darunavir has been researched along with ritonavir in 482 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (ritonavir) | Trials (ritonavir) | Recent Studies (post-2010) (ritonavir) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 5,419 | 1,291 | 2,772 |
| Protein | Taxonomy | darunavir (IC50) | ritonavir (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 6.1 | |
| Bile salt export pump | Homo sapiens (human) | 2.085 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.65 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.1623 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.458 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.067 | |
| Substance-K receptor | Homo sapiens (human) | 2.622 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 2.35 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.076 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.4 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.1933 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.4 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2 | |
| Protease | Human immunodeficiency virus 1 | 4.9253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 83 (17.22) | 29.6817 |
| 2010's | 336 (69.71) | 24.3611 |
| 2020's | 63 (13.07) | 2.80 |
| Authors | Studies |
|---|---|
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB | 1 |
| Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX | 1 |
| Das, D; Gatanaga, H; Ghosh, AK; Grum-Tokars, V; Hussain, AK; Koh, Y; Kovalevsky, AY; Leshchenko, S; Li, J; Maeda, K; Mitsuya, H; Sridhar, PR; Walters, DE; Weber, IT; Wedekind, JE | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI | 1 |
| Baldridge, A; Gemma, S; Ghosh, AK; Koh, Y; Kovalevsky, AY; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H | 1 |
| Ghosh, AK | 1 |
| Chen, HJ; Colletti, L; Degoey, DA; Dekhtyar, T; Flentge, CA; Flosi, WJ; Grampovnik, DJ; Kati, WM; Kempf, DJ; Klein, LL; Mamo, M; Marsh, KC; Mo, H; Molla, A; Morfitt, DC; Nguyen, B; Randolph, JT; Schmidt, JM; Stoll, V; Swanson, SJ; Yeung, CM | 1 |
| Axelsson, L; Ekegren, JK; Hallberg, A; Kihlström, J; Larhed, M; Mahalingam, AK; Samuelsson, B; Unge, T; Wallberg, H; Wannberg, J | 1 |
| Andrews, KT; Butterworth, AS; Eickel, N; Gardiner, DL; MacDonald, T; McCarthy, JS; Peatey, CL; Skinner-Adams, TS; Trenholme, KR | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| De Clercq, E; Liu, X; Pannecouque, C; Zhan, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Arastéh, K; Clumeck, N; De Meyer, S; Lazzarin, A; Lefebvre, E; Muller, H; Peeters, M; Pozniak, A; Rinehart, A | 1 |
| Tachikawa, N | 1 |
| Alcolea, A; Blanco, F; Briz, V; García-Gascó, P; Poveda, E; Soriano, V | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, PE | 1 |
| De Marez, T; De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Parys, W; Sekar, VJ | 1 |
| Esposito, R; Gatell, JM; Goffard, JC; Grinsztejn, B; Katlama, C; Parys, W; Pozniak, A; Rockstroh, J; Stoehr, A; Vangeneugden, T; Vetter, N; Yeni, P | 1 |
| De Paepe, E; De Pauw, M; Hoetelmans, RM; Kestens, D; Lefebvre, E; Sekar, V; Spinosa-Guzman, S; Vangeneugden, T | 1 |
| Edmunds-Ogbuokiri, T | 1 |
| MacArthur, RD | 1 |
| Bellos, N; Clotet, B; Cohen, C; Cooper, D; Farthing, C; Goffard, JC; Haubrich, R; Jayaweera, D; Katlama, C; Lazzarin, A; Lefebvre, E; Markowitz, M; Molina, JM; Ruane, P; Spinosa-Guzman, S; Wilkin, T; Wöhrmann, A | 1 |
| Hill, A; Montaner, J; Smith, C | 1 |
| Hill, A; Moyle, G | 1 |
| Berthé, H; de Truchis, P; Delaugerre, C; Galperine, T; Long, K; Mathez, D; Peytavin, G | 1 |
| Bernard, EJ | 1 |
| Boffito, M; Fletcher, C; Gazzard, B; Hoetelmans, R; Jackson, A; Miralles, D; Moyle, G; Nelson, M; Pozniak, A; Tolowinska, I; Winston, A | 1 |
| Banhegyi, D; Berger, D; de Béthune, MP; De Pauw, M; Lefebvre, E; Madruga, JV; McMurchie, M; Norris, D; Ruxrungtham, K; Spinosa-Guzman, S; Suter, F; Tomaka, F; Vangeneugden, T | 1 |
| Cohen, C; Grinsztejn, B; Katlama, C; Lefebvre, E; Meyer, SD; Miralles, D; Molina, JM; Parys, W; Pedro, Rde J; Timerman, A; Vangeneugden, T | 1 |
| De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Peeters, M; Sekar, VJ | 1 |
| Hill, A; Molina, JM | 1 |
| De Smedt, G; Hoetelmans, RM; Kakuda, TN; Lefebvre, E; Peeters, M; Schöller-Gyüre, M; Sekar, V; Woodfall, B | 1 |
| Arastéh, K; Rittweger, M | 1 |
| Gebo, K; Hill, A | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| de Mendoza, C; Pattery, T; Poveda, E; Soriano, V; Villacian, J; Vispo, E | 1 |
| Hall, D | 1 |
| De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Sekar, VJ; Vangeneugden, T | 1 |
| Baert, L; Borghys, H; Clessens, E; Jonckers, TH; Lachau-Durand, S; Rosier, J; Schueller, L; Van Den Mooter, G; Van Gyseghem, E; Van Remoortere, P; Wigerinck, P | 1 |
| De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Spinosa-Guzman, S; Vangeneugden, T | 1 |
| Bruzzone, B; Cenderello, G; Dentone, C; Di Biagio, A; Ferrea, G; Icardi, G; Mularoni, A; Rosso, R; Viscoli, C | 1 |
| Andres, DA; Coffinier, C; Farber, EA; Fong, LG; Hrycyna, CA; Hudon, SE; Lee, R; Miner, JH; Nobumori, C; Spielmann, HP; Young, SG | 1 |
| De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Vangeneugden, T | 1 |
| Bollens, D; Bonarek, M; Breilh, D; Fleury, H; Girard, PM; Joubert, LM; Neau, D; Pellegrin, I; Pellegrin, JL; Saux, MC; Thiébaut, R; Winters, B; Wittkop, L | 1 |
| De Marez, T; De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, V; Vangeneugden, T | 2 |
| Andrade-Villanueva, J; De Meyer, S; De Pauw, M; Dejesus, E; Fourie, J; Khanlou, H; Lefebvre, E; Ortiz, R; Spinosa-Guzman, S; van Lunzen, J; Vangeneugden, T; Voronin, E | 1 |
| De Pauw, M; Felicione, E; Guzman, SS; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Vangeneugden, T | 1 |
| Cedeño, S; Clotet, B; Else, L; Khoo, S; Llibre, JM; Miranda, C; Moltó, J; Pérez-Alvarez, N; Santos, JR; Valle, M | 1 |
| de Béthune, MP; De Meyer, SM; Miralles, GD; Spinosa-Guzman, S; Vangeneugden, TJ | 1 |
| Enejosa, J; Hinkle, J; Kearney, BP; Mack, R; Mathias, AA; Piliero, PJ; Sekar, V; Shen, G; Tomaka, F | 1 |
| DeJesus, E; Gathe, JC; Gottlieb, MS; Greenberg, ML; Guittari, CJ; Zolopa, AR | 1 |
| Rawizza, HE; Sax, PE | 1 |
| Cerini, C; Fasan, S; Giacomet, V; Marchetti, G; Meroni, L; Pradella, A; Vanzulli, A; Viganò, A; Zuccotti, GV | 1 |
| Beatty, G; de Béthune, MP; Hill, A; Lefebvre, E; Opravil, M; Pozniak, A | 1 |
| Louis, JM; Sayer, JM | 1 |
| Barrail-Tran, A; Chaix, ML; Delfraissy, JF; Ghosn, J; Pallier, C; Sahali, S | 1 |
| Cuyckens, F; Lachau-Durand, S; Mannens, G; Raoof, A; van Hoof, B; Vermeir, M | 1 |
| Brun-Vézinet, F; Calvez, V; Descamps, D; Felices, M; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Peytavin, G; Roquebert, B; Yeni, P | 1 |
| Hidalgo Tenorio, C; Pasquau Liaño, J | 1 |
| Estrada, V; Fuster, M | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| Arazo Garcés, P; Omiste Sanvicente, T | 1 |
| Antela López, A | 1 |
| Clotet, B; Moltó, J; Valle, M | 1 |
| de Béthune, MP; De Meyer, S; De Paepe, E; DeMasi, R; Hill, A; Picchio, G | 1 |
| Diego Miralles, G; Lefebvre, E; Sekar, V; Tomaka, F; Van Baelen, B; Vandevoorde, A; Vangeneugden, T | 1 |
| Cattaneo, D; Cortinovis, M; Maggiolo, F; Ripamonti, D; Suter, F | 1 |
| Sax, PE | 1 |
| De Meulder, M; Gisslén, M; Izadkhashti, A; Mallon, PW; Price, RW; Timmerman, P; Yilmaz, A | 1 |
| Battegay, M; Marzolini, C; Mayr, M; Mertz, D | 1 |
| Bernardini, C; Bruzzone, B; Di Biagio, A; Icardi, G; Rosso, R; Secondo, G; Viscoli, C | 1 |
| de Béthune, MP; De Meyer, S; De Paepe, E; Dierynck, I; Lathouwers, E; Lefebvre, E; Picchio, G; Spinosa-Guzman, S; Van Baelen, B; Vangeneugden, T | 1 |
| Abeele, CV; Cassetti, I; Dierynck, I; Girard, PM; Jayaweera, D; Lavreys, L; Mills, AM; Nelson, M; Ruxrungtham, K; Sekar, V; Workman, C | 1 |
| Calvez, V; Hill, A; Marcelin, AG | 1 |
| Jennings, SH; Kashuba, AD; Rezk, NL; White, NR | 1 |
| De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Pozniak, A; Sekar, V; Vangeneugden, T | 1 |
| Blanche, S; Bologna, R; Cahn, P; Dierynck, I; Flynn, P; Fortuny, C; Rugina, S; Sekar, V; Spinosa-Guzman, S; van Baelen, B; Vis, P | 1 |
| Arastéh, K; De Meyer, S; Grinsztejn, B; Hoy, J; Jayaweera, D; Pozniak, A; Roberts, A; Tomaka, F; Vangeneugden, T; Yeni, P | 1 |
| Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Pialoux, G; Piketty, C; Roquebert, B; Taburet, AM; Yazdanpanah, Y | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Arribas, JR; Clumeck, N; Fätkenheuer, G; Gerstoft, J; Hill, A; Horban, A; Moecklinghoff, C; Nelson, M; Pulido, F; Stark, T; van Delft, Y | 1 |
| Annaert, P; Augustijns, P; Camus, S; Snoeys, J; Van Pelt, J; Ye, ZW | 1 |
| Arribas, JR | 1 |
| Castagna, A; De Wit, S; Florence, E; Hill, A; Marks, S; Ribera, E; van Delft, Y; Vanaken, H | 1 |
| Baraboutis, IG; Georgiou, O; Kotsianopoulou, M; Papastamopoulos, V; Samarkos, M; Skoutelis, AT; Vrionis, E | 1 |
| Aegerter, P; Blanche, S; Buyck, JF; Chaix, ML; de Truchis, P; Delaugerre, C; Force, G; Mortier, E; Peytavin, G; Rouveix, E; Viard, JP; Zucman, D | 1 |
| Carper, MJ; Lei, X; Ramanadham, S; Richmond, SR; Yarasheski, KE; Zhang, S | 1 |
| Appelbaum, JS; Bellman, P; Gathe, J; Gottlieb, MS; Hoogstoel, A; Lalezari, J; Nijs, S; Ryan, R; Sension, MG; Towner, W; Van Solingen-Ristea, R; Witek, J; Wohlfeiler, M | 1 |
| Berger, DS; Cheng, AK; Chuck, SL; Enejosa, JV; Kearney, BP; Lampiris, H; Zhong, L; Zolopa, AR | 1 |
| De Luca, A; Navarra, P; Pinnetti, C; Ragazzoni, E; Tamburrini, E | 1 |
| McKeage, K; Scott, LJ | 1 |
| Hull, MW; Montaner, JS | 1 |
| De Paepe, E; De Pauw, M; Hoetelmans, RM; Sekar, V; Spinosa-Guzman, S; Stevens, T; Tomaka, F | 1 |
| Flexner, C; Lee, L; Pham, P; Shen, P; Soon, GH; Yong, EL | 1 |
| Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A | 1 |
| Barbanoj, MJ; Cedeño, S; Clotet, B; Miranda, C; Moltó, J; Mothe, B; Negredo, E; Santos, JR; Valle, M; Videla, S; Yritia, M | 1 |
| Flexner, C; Lee, LS; Pham, P; Shen, P; Soon, GH; Yong, EL | 1 |
| Bellagamba, R; Ivanovic, J; Mazzitelli, L; Narciso, P; Nicastri, E; Signore, F; Tempestilli, M; Tommasi, C; Vallone, C | 1 |
| De Pauw, M; Hoetelmans, R; Lefebvre, E; Sekar, V; Tomaka, F; van den Brink, W; Vangeneugden, T | 1 |
| Borland, J; Chen, S; Ishibashi, T; Lou, Y; Min, SS; Patel, P; Piscitelli, SC; Song, I | 1 |
| Chen, L; Demasi, R; Girard, PM; Lavreys, L; Nelson, M; Sekar, V; Smets, E | 1 |
| Annaert, P; Augustijns, P; Holmstock, N; Mols, R | 1 |
| Beijnen, JH; Huitema, AD; Mulder, JW; Ter Heine, R; van Gorp, EC; Wagenaar, JF | 2 |
| Berginc, K; Kristl, A; Trontelj, J | 1 |
| Bar-Magen, T; Donahue, DA; Kuhl, BD; Liang, C; Sloan, RD; Wainberg, MA | 1 |
| Berckmans, C; De Pauw, M; Hoetelmans, R; Lavreys, L; Sekar, V; Spinosa-Guzman, S; Van de Casteele, T; Vangeneugden, T | 1 |
| DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J | 1 |
| Crespo, M; Curran, A; Deig, E; Domingo, P; Gutirerrez, M; Imaz, A; Lopez, RM; Mateo, G; Ocaña, I; Ribera, E | 1 |
| Algarte-Genin, M; Calvez, V; Duvivier, C; Flandre, P; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Meynard, JL; Molina, JM; Pakianather, S; Peytavin, G; Poirot, C; Valantin, MA | 1 |
| Brun-Vézinet, F; Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Roquebert, B; Taburet, AM; Yazdanpanah, Y | 1 |
| Algarte-Genin, M; Duvivier, C; Flandre, P; Girard, PM; Hoen, B; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Molina, JM; Pakianather, S; Peytavin, G; Valantin, MA | 1 |
| Azijn, H; Daems, B; de Béthune, MP; Nijs, S; Picchio, G; Tambuyzer, L; Vingerhoets, J | 1 |
| Averitt Bridge, D; Currier, J; Falcon, R; Feinberg, J; Hagins, D; Mrus, J; Ryan, R; Squires, K; Tennenberg, A; Zorrilla, CD | 1 |
| Corbett, C; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Peeters, MP; Schöller-Gyüre, M; Snoeck, E; Vingerhoets, J; Vis, P; Wade, JR; Woodfall, BJ | 1 |
| Barrail-Tran, A; Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Goldwirt, L; Katlama, C; Molina, JM; Piketty, C; Taburet, AM; Yazdanpanah, Y | 1 |
| Aung, GL; Kawamoto, LS; O'Brien, JG; Tien, PG | 1 |
| Clotet, B; Grinsztejn, B; Haubrich, R; Katlama, C; Mills, A; Molina, JM; Nijs, S; Towner, W; Trottier, B; Vingerhoets, J; Witek, J; Woodfall, B | 1 |
| Barbanoj, MJ; Cedeño, S; Clotet, B; Miranda, C; Moltó, J; Negredo, E; Valle, M | 1 |
| Alas, B; Perniciaro, A; Ruane, P; Ryan, R; Witek, J | 1 |
| Berginc, K; Kristl, A; Trdan, T; Trontelj, J | 1 |
| Bravo, I; Clotet, B; Domingo, P; Ferrer, E; Imaz, A; Llibre, JM; Podzamczer, D; Ribera, E; Santos, JR; Videla, S | 1 |
| Parienti, JJ | 1 |
| Allsop, JM; Garvey, L; Higgs, C; Hill, A; Mohammed, P; Nelson, M; Taylor-Robinson, SD; Winston, A | 1 |
| Bracciale, L; Cauda, R; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Navarra, P; Parruti, G; Prosperi, M; Ragazzoni, E | 1 |
| Arribas, JR; Pérez-Valero, I | 1 |
| Falcon, R; Jennings, S; Kashuba, A; Mrus, J; Patterson, K | 1 |
| Annemans, L; Hill, AM; Mauskopf, J; Smets, E | 1 |
| Bellos, N; Clotet, B; Hill, AM; Johnson, M; Smets, E; Stoll, M | 1 |
| Brogan, A; Martin, S; Mauskopf, J; Smets, E | 1 |
| Allegri, G; Annemans, L; Caekelbergh, K; Hemmet, L; Löthgren, M; Moeremans, K; Smets, E; Wyffels, V | 1 |
| Brogan, A; Mauskopf, J; Smets, E; Talbird, SE | 1 |
| Allegri, G; Hemmett, L; Hjelmgren, J; Moeremans, K; Smets, E | 1 |
| Allegri, G; Gebo, K; Hemmett, L; Hill, AM; Löthgren, M; Smets, E | 1 |
| Brun-Vézinet, F; Calvez, V; Charpentier, C; Descamps, D; Fourati, S; Katlama, C; Lambert-Niclot, S; Larrouy, L; Marcelin, AG; Soulié, C; Visseaux, B; Wirden, M; Yeni, P | 1 |
| Arribas, JR; Hill, A; Moecklinghoff, C; Pulido, F; Van Delft, Y | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Lavreys, L; Picchio, G; Van de Casteele, T | 1 |
| Cahn, P; De Doncker, P; Fourie, J; Grinsztejn, B; Hodder, S; Lathouwers, E; Molina, JM; Ruxrungtham, K; Tomaka, F; Van De Casteele, T; Workman, C | 1 |
| De La Rosa, G; Fullerton, DS; Mrus, JM; Smets, E | 1 |
| Abel, S; Davis, J; Hamlin, J; Hoetelmans, RM; Kakuda, TN; Mack, R; Ndongo, N; Petit, W; Ridgway, C; Schöller-Gyüre, M; Sekar, V; Tweedy, S | 1 |
| Cattaneo, D; Gervasoni, C | 1 |
| Aboulker, JP; Barrail-Tran, A; Braun, J; Charreau, I; de Castro, N; Delaugerre, C; Goldwirt, L; Lascoux-Combe, C; Molina, JM; Raffi, F; Taburet, AM | 1 |
| Currier, JS; De La Rosa, G; Martorell, C; Mrus, J; Osiyemi, O; Ryan, R; Yin, MT | 1 |
| Arribas, J; Banhegyi, D; Clumeck, N; Hill, A; Moecklinghoff, C; Rieger, A; Schmidt, W; Van Delft, Y | 1 |
| Aslanyan, S; Kohlbrenner, V; Kort, JJ; Robinson, P; Sabo, JP; Scherer, J | 1 |
| Antinori, A; Baldanti, F; De Luca, A; Di Giambenedetto, S; Di Perri, G; Gianotti, N; Maserati, R; Micheli, V; Narciso, P; Perno, CF; Prosperi, MC; Santoro, MM; Zazzi, M | 1 |
| Phung, BC; Yeni, P | 1 |
| Amara, A; Back, D; Boffito, M; Gazzard, B; Higgs, C; Jackson, A; Khoo, S; Moyle, G; Seymour, N | 1 |
| Desai, PB; Fichtenbaum, CJ; Sallans, L; Samineni, D | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| Aïssi, E; Ettahar, N; Huleux, T; Massongo, M; Melliez, H; Pasquet, A; Yazdanpanah, Y | 1 |
| Acosta, EP; Bastow, B; Berzins, BI; Eron, JJ; Gallien, S; Kim, PS; Kuritzkes, DR; Matining, RM; Taiwo, B; Wilson, CC; Zheng, L | 1 |
| Nsanzabana, C; Rosenthal, PJ | 1 |
| Algarte-Genin, M; Calvez, V; Duvivier, C; Flandre, P; Girard, PM; Haim-Boukobza, S; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Peytavin, G; Valantin, MA; Yazdanpanah, Y | 1 |
| Abbas, R; Back, D; Boffito, M; Egan, D; Gazzard, B; Gedela, K; Higgs, C; Jackson, A; Khoo, S; Liptrott, N; Watson, V | 1 |
| Baldelli, S; Boreggio, G; Cattaneo, D; Clementi, E; Cozzi, V; Fucile, S; Gervasoni, C; Landonio, S; Meraviglia, P; Rizzardini, G | 1 |
| Bonora, S; Borghi, V; Corsi, P; De Luca, A; Leoncini, F; Meraviglia, P; Sterrantino, G; Trotta, M; Zaccarelli, M; Zazzi, M | 1 |
| Brogan, AJ; Martin, S; Mauskopf, J; Talbird, SE | 1 |
| Alvanzo, AA; Gruber, VA; Ma, Q; McCance-Katz, EF; Moody, DE; Morse, GD; Pade, PA; Prathikanti, S; Rainey, PM | 1 |
| Dronda, F; García-Blázquez, V; Lourido-García, D; Vicente-Bártulos, A | 1 |
| Ajana, F; Cabiè, A; Curjol, A; Cuzin, L; Flandre, P; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Meynard, JL; Morand-Joubert, L; Ponscarme, D; Schneider, L; Slama, L; Taburet, AM; Valantin, MA | 1 |
| Ainsworth, J; Cook, R; Dufty, N; Gandhi, K; Hickinbottom, G; Khonyongwa, K; Okoli, C; Owen, A; Siccardi, M; Taylor, S; Thomas-William, S; Watson, J | 1 |
| Anderson, PL; Aquilante, CL; Christians, U; Daily, EB; Hoffman, KL; Hopley, CW; Kiser, JJ; Kosmiski, LA; Predhomme, JA; Schniedewind, B; Sidhom, MS | 1 |
| Hodder, S; Jayaweera, D; Mrus, J; Ryan, R; Witek, J | 1 |
| Gatanaga, H; Kikuchi, Y; Nishijima, T; Oka, S; Teruya, K; Tsukada, K | 1 |
| Blanco, JR; Oteo, JA; Pérez-Martínez, L; Pérez-Matute, P | 1 |
| Abongomera, G; Back, D; Boffito, M; Dickinson, L; Gazzard, B; Gedela, K; Jackson, A; Khoo, S; Moyle, G; Taylor, J | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Anceau, A; Gostkorzewicz, J; Hill, A; Ledesma, F; Moecklinghoff, C; Pasquau, J | 1 |
| Auclair, M; Capeau, J; Capel, E; Caron-Debarle, M | 1 |
| Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Rami, A; Vittecoq, D; Yazdanpanah, Y; Yeni, P | 1 |
| Bánhegyi, D; da Cunha, CA; De Meyer, S; Katlama, C; Rachlis, A; Schneider, S; Tomaka, F; Van De Casteele, T; Vandevoorde, A; Workman, C | 1 |
| Aberg, JA; De La Rosa, G; Falcon, R; Gupta, SK; Landay, A; Overton, ET; Ryan, R; Sax, PE; Tebas, P | 1 |
| Arribas, J; Hill, A; Moecklinghoff, C; Pulido, F | 1 |
| Algarte-Genin, M; Calvez, V; Delaugerre, C; Flandre, P; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Morand-Joubert, L; Peytavin, G; Sayon, S; Valantin, MA | 1 |
| Arribas, JR; Clumeck, N; Hill, A; Moecklinghoff, C; Nelson, M; van Delft, Y | 1 |
| Algarte Genin, M; Cuzin, L; de Kerviler, E; Flandre, P; Inaoui, R; Katlama, C; Kolta, S; Meynard, JL; Ponscarme, D; Slama, L; Valantin, MA | 1 |
| Cedeño, S; Clotet, B; Miranda, C; Moltó, J; Negredo, E; Valle, M | 1 |
| Arribas, J; Hill, A; Moecklinghoff, C; van Delft, Y; Xi, N | 1 |
| Bertucci, R; Bonora, S; Calcagno, A; Cusato, J; D'Avolio, A; Di Perri, G; Marinaro, L; Siccardi, M; Simiele, M; Yilmaz, A | 1 |
| Hill, A; Moecklinghoff, C; Winston, A | 1 |
| Feinberg, J; Robertson, J | 1 |
| Asher Prince, HM; Brown, KC; Cohen, MS; Jennings, SH; Kashuba, AD; Malone, SA; Patterson, KB; Shaheen, NJ; Spacek, M | 1 |
| Bravo, I; Clotet, B; Llibre, JM; Moltó, J; Negredo, E; Ornelas, A; Paredes, R; Santos, JR | 1 |
| Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J | 1 |
| Bigoloni, A; Carini, E; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Piatti, P; Salpietro, S; Spagnuolo, V; Vinci, C | 1 |
| Fuchs, D; Gisslén, M; Hagberg, L; Svennerholm, B; Zetterberg, H | 1 |
| Bocket, L; Calvez, V; Dos Santos, G; Flandre, P; Fourati, S; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Pakianather, S; Sayon, S; Soulie, C; Valantin, MA; Wirden, M | 1 |
| Ananworanich, J; Burger, D; Chokephaibulkit, K; Gorowara, M; Kerr, SJ; Pasomsap, C; Phongsamart, W; Prasitsuebsai, W; Puthanakit, T; Sekar, V; Sophonphan, J; Suwanlerk, T; Vanprapar, N; Wittawatmongkol, O | 1 |
| Calza, L; Manfredi, R | 1 |
| Chermak, A; Courbon, E; Duvivier, C; Flandre, P; Fourn, E; Ghosn, J; Houssaini, A; Katlama, C; Lambert-Niclot, S; Murphy, R; Peytavin, G; Schneider, L; Simon, A; Slama, L | 1 |
| DeJesus, E; Khanlou, H; Lathouwers, E; Lefebvre, E; Opsomer, M; Orkin, C; Stoehr, A; Supparatpinyo, K; Tomaka, F; Van de Casteele, T | 1 |
| Allavena, C; Bouquié, R; Dailly, E; Deslandes, G; Jolliet, P; Raffi, F | 1 |
| Ambrosioni, J; Assouline, B; Calmy, A; Daali, Y; Desmeules, J; Fathi, M; I Lorenzini, K; Rebsamen, M; Samer, CF | 1 |
| Butterton, JR; Feng, HP; Hughes, EA; Hulskotte, EG; O'Mara, E; Treitel, MA; van Zutven, MG; Wagner, JA; Xuan, F; Youngberg, SP | 1 |
| Flexner, C; Lee, LS; Pham, P | 1 |
| Back, D; Croucher, A; Else, LJ; Khoo, S; Mora-Peris, B; Scullard, G; Vera, JH; Winston, A | 1 |
| Amano, M; Aoki, M; Campbell, JR; Das, D; Ghosh, AK; Mitsuya, H; Rao, KV; Salcedo-Gómez, PM; Tojo, Y; Xu, CX | 1 |
| Bonfanti, P; Carenzi, L; Celesia, BM; Corsi, P; De Socio, G; Di Biagio, A; Franzetti, M; Grosso, C; Guastavigna, M; Madeddu, G; Maggi, P; Martinelli, C; Menzaghi, B; Molteni, C; Orofino, G; Parruti, G; Penco, G; Quirino, T; Ricci, E; Vichi, F | 1 |
| Arathoon, E; Baraldi, E; Lavreys, L; Lim, PL; Opravil, M; Schneider, S; Van De Casteele, T | 1 |
| DeMasi, R; Kakuda, TN; Mohammed, P; van Delft, Y | 1 |
| Benalycherif, A; De Truchis, P; Delassus, JL; Descamps, D; Duvivier, C; Landman, R; Peytavin, G; Tegna, L; Weiss, L; Zucman, D | 1 |
| Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M | 1 |
| Cahn, P; Domingo, P; Hodder, S; Lathouwers, E; Opsomer, M; Sension, M; Tomaka, F; Van de Casteele, T | 1 |
| Cedeño, S; Clotet, B; Miranda, C; Moltó, J; Owen, A; Pushpakom, S; Valle, M; Xinarianos, G | 1 |
| Di Nicola, M; Falasca, K; Pizzigallo, E; Ucciferri, C; Vecchiet, J; Vignale, F | 1 |
| Alfaro, RM; Boyd, SD; Calderon, MM; Chairez, C; Hadigan, C; Kovacs, JA; McManus, M; Nieman, LK; Pau, AK; Penzak, SR | 1 |
| Baeten, B; De La Rosa, G; De Meyer, S; Lathouwers, E; Picchio, G; Tomaka, F; Van de Casteele, T | 1 |
| Berhan, A; Berhan, Y | 1 |
| Berzins, BI; Eron, JJ; Jennings, A; Kim, PS; Kuritzkes, DR; Lederman, MM; Matining, RM; Rinaldo, CR; Taiwo, B; Wilson, CC; Zheng, L | 1 |
| Baran, RW; Caro, JJ; Dietz, B; Migliaccio-Walle, K; Möller, J; Pei, PP; Simpson, KN; Woodward, W | 1 |
| Bridge, DA; Currier, J; Dayaram, YK; Feinberg, J; Mrus, J; Ryan, R; Seyedkazemi, S; Squires, K | 1 |
| Lanzafame, M; Lattuada, E; Rigo, F; Vento, S | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Baugh, B; Brown, K; Coate, B; Falcon, R; Kakuda, TN; Mrus, J; Osiyemi, OO; Verboven, P; Wright, R; Yasin, S; Zorrilla, CD | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E | 1 |
| Acosta, EP; Adeyemi, O; Berzins, B; Castro, J; Eron, JJ; Kuritzkes, DR; Lalezari, J; Lu, D; Ryscavage, P; Swindells, S; Taiwo, B; Tsibris, A | 1 |
| Blanco, JL; Brunet, M; Calvo, M; Gatell, JM; González, A; Hidalgo, S; Laguno, M; Loncà, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Muñoz, A; Pérez, I | 1 |
| Arnalich, F; Arribas, JR; Bayón, C; Bernardino, JI; Estébanez, M; Gaya, F; González-Baeza, A; Hernando, A; Lagarde, M; Monge, S; Montes-Ramírez, ML; Pérez-Valero, I; Pulido, F; Rubio, R; Zamora, FX | 1 |
| Foisy, MM; Hall, JJ; Houston, S; Hughes, CA; Shafran, S | 1 |
| Arribas, J; Delft, Yv; Hill, A; Moecklinghoff, C; Pulido, F | 1 |
| Baroncelli, S; Cavalli, A; Cirioni, O; Cusato, M; Floridia, M; Fragola, V; Francisci, D; Galluzzo, CM; Parruti, G; Pirillo, MF; Regazzi, M; Sighinolfi, L; Sozio, F; Tedeschi, S; Villani, P; Vivarelli, A; Volpe, A; Weimer, LE | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Carli, F; Cossarizza, A; Garau, M; Garlassi, E; Guaraldi, G; Lattanzi, A; Nardini, G; Orlando, G; Termini, R; Vernacotola, L; Zona, S | 1 |
| Baran, RW; Desai, K; Dietz, B; Gooch, K; Möller, J; Simpson, K; Van de Steen, O | 1 |
| Benmarzouk-Hidalgo, OJ; Gutiérrez-Valencia, A; Lopez-Cortes, LF; Martín-Peña, R; Pérez-Romero, P; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| BenMarzouk-Hidalgo, OJ; Gutiérrez-Valencia, A; López-Cortés, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 4 |
| Crespo, M; Curran, A; Domingo, P; Fernández, I; Imaz, A; Iribarren, JA; Knobel, H; Martínez, E; Monteiro, P; Peñaranda, M; Podzamczer, D; Villar, J | 1 |
| Bernardino, JI; Carton, JA; Curran, A; Domingo, P; Ferrer, E; Gatell, JM; Gonzalez-Cordon, A; Gutierrez, F; Martinez, E; Murillas, J; Negredo, E; Peraire, J; Perez, I; Pich, J; Podzamczer, D; Portilla, J; Santos, I | 1 |
| BenMarzouk-Hidalgo, OJ; Gutierrez-Valencia, A; Lluch, A; López-Cortés, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Battegay, M; Elzi, L; Lakatos, B; Marzolini, C; Stoeckle, M | 1 |
| Aoki, T; Gatanaga, H; Honda, H; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Afonso, P; Auclair, M; Capeau, J; Capel, E; Caron-Debarle, M | 1 |
| Bancalero, P; Chueca, N; García, C; Jiménez, P; Macías, J; Márquez, M; Merino, D; Muñoz, L; Ojeda, G; Pasquau, J; Pineda, JA; Recio, E | 1 |
| Mishra, T; Shrivastav, PS | 1 |
| Fletcher, CV; Podany, AT; Robbins, BL; Winchester, LC | 1 |
| Blum, JD; Kiser, JJ; MacBrayne, CE | 1 |
| Hillewaert, V; Hoetelmans, RM; Iterbeke, K; Kakuda, TN; Opsomer, M; Petrovic, R; Timmers, M; Van De Casteele, T | 1 |
| Acosta, EP; Armstrong, WS; Arrendale, RF; Delille, CA; Easley, KA; Lennox, JL; Marconi, VC; Ofotokun, I; Pruett, ST; Sheth, AN; Vunnava, A | 1 |
| Arribas, JR; Pozniak, AL | 1 |
| Antinori, A; Brennan, C; Clotet, B; Dumitru, I; Fehr, J; Feinberg, J; Fujiwara, T; Harris, J; Khuong-Josses, MA; Min, S; Ortiz, R; Pokrovskiy, V; Saag, M; van Lunzen, J | 1 |
| Dupuis, A; Garcia, M; Le Moal, G; Roblot, F; Rochette, N; Venisse, N | 1 |
| Abdi, AM; Bonora, S; Calcagno, A; D'Avolio, A; De Nicolò, A; Di Perri, G; Simiele, M | 1 |
| Aouri, M; Arab-Alameddine, M; Buclin, T; Cavassini, M; Csajka, C; Décosterd, LA; Fayet-Mello, A; Gatri, M; Guidi, M; Ledergerber, B; Lubomirov, R; Panchaud, A; Rentsch, K; Rotger, M; Telenti, A; Widmer, N | 1 |
| Campbell, SE; Medlock, MM; Morgan, RE; Small, DS; Sponseller, CA; Yu, CY | 1 |
| Asensi, V; Bachiller, P; Blanco, JR; Camacho, A; Castaño, M; Clotet, B; Curto, J; Espinosa, N; Flores, J; Force, L; Gomez-Sirvent, JL; Imaz, A; Iribarren, JA; Knobel, H; López Bernaldo De Quirós, JC; Martín, T; Moreno, V; Ocampo, A; Perez, I; Podzamczer, D; Rojas, J; Rozas, N; Valencia, E; Vergas, J; Viciana, P | 1 |
| Adriaenssen, I; Brogan, AJ; Manuel, SA; Mauskopf, JA; Smets, E | 1 |
| Arribas, JR; Bernardino, JI; Estébanez, M; González-García, JJ; Mingorance, J; Montes, ML; Pérez-Valero, I; Stella-Ascariz, N; Zamora, FX | 1 |
| Hazuda, DJ; Johnson, AM; Lifson, JD; Ling, B; Piatak, M; Rogers, L; Russell-Lodrigue, K; Veazey, RS | 1 |
| Ballow, C; Battegay, M; Elgadi, M; Feifel, U; Fuhr, R; Girlich, B; Haschke, M; Kort, J; Lang, B; Li, Y; Sabo, JP; Schobelock, M | 1 |
| Allavena, C; Antinori, A; Arribas, JR; Babiker, AG; Chêne, G; Delfraissy, JF; George, EC; Grarup, J; Hudson, F; Jansson, PO; Molina, JM; Pozniak, A; Raffi, F; Richert, L; Saillard, J; Schwimmer, C; Van Leeuwen, R; Vella, S; Wallet, C | 1 |
| Carda-Broch, S; Casas-Breva, I; Esteve-Romero, J; Peris-Vicente, J; Villarreal-Traver, M | 1 |
| Hillewaert, V; Hoetelmans, RM; Kakuda, TN; Leopold, L; Timmers, M; Tomaka, FL; Van De Casteele, T | 1 |
| Chokephaibulkit, K; Cressey, TR; Kongstan, N; Lappra, K; Phongsamart, W; Rungmaitree, S; Wittawatmongkol, O | 1 |
| Becker, A; Desprez, S; Froidure, M; Gagneux, M; Huguet, D; Leduc, D; Legout, L; Sifaoui, F; Vignoli, P | 1 |
| Nguyen, DN; Van den Mooter, G | 1 |
| Aberg, JA; Ma, Q; Malvestutto, CD; Morse, GD; Underberg, JA | 1 |
| Bigoloni, A; Boeri, E; Castagna, A; Cavarelli, M; Galli, A; Mainetti, L; Nozza, S; Pignataro, AR; Sampaolo, M; Scarlatti, G; Tolazzi, M | 1 |
| Imai, Y; Kawamoto, M; Kohara, N; Sekiya, H; Togo, M; Yoshimura, H | 1 |
| Bañón, S; Casado, JL; Moreno, A; Moreno, S; Perez-Elías, MJ; Rodriguez, MA; Santiuste, C | 1 |
| Blanche, S; Flynn, P; Giaquinto, C; Kakuda, TN; Komar, S; Lathouwers, E; Noguera-Julian, A; Opsomer, M; Van de Casteele, T; Welch, S | 1 |
| Arribas, J; Hill, A; Leeansyah, E; Lewin, SR; Moecklinghoff, C; Solomon, A; Tennakoon, S; Van Delft, Y | 1 |
| Berrio-Galan, D; Bravo, I; Clotet, B; Llibre, JM; Miranda, C; Moltó, J; Paredes, R; Pérez-Alvarez, N; Pérez-Alvarez, S; Santos, JR | 1 |
| Anderson, D; Brinson, C; Cho, M; Coate, B; Kakuda, TN; Ramgopal, M; Ruane, PJ; Ryan, R | 1 |
| Bateson, R; Calvez, V; Ceccherini-Silberstein, F; Clotet, B; Cozzi-Lepri, A; Flandre, P; Grarup, J; Günthard, HF; Hoogstoel, A; Incardona, F; Kaiser, R; Lavreys, L; Ledergerber, B; Lundgren, J; Marcelin, AG; Mercedes Santoro, M; Nelson, M; Nijs, S; Opsomer, M; Paredes, R; Perno, CF; Sonnerborg, A; Tambuyzer, L; Vingerhoets, J | 1 |
| Hiep, DM; Li, MS; Mai, BK; Ngo, ST | 1 |
| Back, D; Clotet, B; Curran, A; Di Yacovo, MS; Else, L; Ferrer, E; Gisslén, M; Moltó, J; Niubò, J; Podzamczer, D; Tiraboschi, JM; Vila, A; Zetterberg, H | 1 |
| Martin-Carpenter, L; Quercia, R; Roberts, J; Zala, C | 1 |
| Minaeva, SV; Moshkovich, GF | 1 |
| Bologna, R; Hendrickx, A; Kakuda, TN; Kumarasamy, N; Lathouwers, E; Opsomer, M; Pilotto, JH; Tomaka, FL; Van de Casteele, T; Violari, A | 1 |
| Aweeka, F; Baugh, BP; Brown, TT; Cohn, SE; Currier, JS; Godfrey, C; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Para, MF; Patterson, KB; Ribaudo, HJ; Sagar, M; Villasis-Keever, A | 1 |
| Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Manfredi, R; Motta, R; Verucchi, G; Viale, P | 1 |
| Huhn, GD; Livak, B; Sigman, A | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Best, BM; Burchett, SK; Capparelli, EV; Cressey, TR; Kreitchmann, R; Mirochnick, M; Mofenson, LM; Rungruengthanakit, K; Shapiro, D; Smith, E; Stek, A; Wang, J | 1 |
| Crauwels, H; de Smedt, G; Iterbeke, K; Kakuda, TN; Opsomer, M; Tomaka, F; van de Casteele, T; Vanveggel, S | 1 |
| Ahmed, N; Ainsworth, J; Okoli, C | 1 |
| Aris, AB; Jaafar, J; Madhavi, G; Majid, ZA; Reddy, AV; Talib, J; Umar, K | 1 |
| Andrade, A; Eron, JJ; Fichtenbaum, CJ; Gandhi, RT; Haubrich, RH; Johnson, VA; Klingman, KL; Mollan, KR; Na, L; Smeaton, L; Tashima, KT | 1 |
| Fairlie, L; Kindra, G; Moultrie, H; Sipambo, N | 1 |
| Burgos, J; Crespo, M; Curran, A; Falcó, V; López, RM; Martí, R; Melià, MJ; Navarro, J; Ocaña, I; Pérez, M; Ribera, E | 1 |
| Bellistrì, GM; Cannizzo, ES; d'Arminio Monforte, A; Garau, M; Mancusi, D; Marchetti, G; Savoldi, A; Termini, R; Tincati, C | 1 |
| Burger, D; Colbers, A; Greupink, R; Litjens, C; Russel, FG | 1 |
| Brennan, C; Cavassini, M; Clotet, B; de Oliveira, CF; Givens, N; Henry, K; Kulagin, V; Lazzarin, A; Molina, JM; van Lunzen, J | 1 |
| Blanes, M; Calabuig, E; Cuellar, S; Di Benedetto, N; Lacruz, J; López, J; Montero-Alonso, M; Salavert, M | 1 |
| Burling, K; Cason, J; Fox, J; Hamzah, L; Ibrahim, F; Iveson, H; Jendrulek, I; Kulasegaram, R; Mant, C; Post, FA; Taylor, C; Teague, A; Tiraboschi, JM; Toby, M; Wandolo, E | 1 |
| Arribas, JR; Babiker, A; Bernardino, JI; Buño, A; Castagna, A; Chene, G; De Wit, S; Gerstoft, J; Girard, PM; Katlama, C; Mallon, PW; Mocroft, A; Raffi, F; Reiss, P; Richert, L; Russell, C; Wallet, C | 1 |
| De Saram, S; Dhairyawan, R; Flanagan, S | 1 |
| Fulco, PP; Gomes, D; Nixon, D; Smith, K | 1 |
| Brouillette, M; Farr, AM; Johnston, SS; Ritchings, C; Rosenblatt, L | 1 |
| Bloch, M; Carr, A; Lee, FJ; Mackenzie, N; Marriott, D; Richardson, R | 1 |
| Arribas, JR; Elbirt, D; Girard, PM; Hadacek, MB; Hill, A; Marcelin, AG; Paton, N; Winston, A | 1 |
| Back, D; Boffito, M; Dickinson, L; Khoo, S; Siccardi, M; Winston, A | 1 |
| Aghokeng, AF; Bertagnolio, S; Carmona, S; Chua, A; De Oliveira, T; Fitzgibbon, JE; Fokam, J; Frenkel, LM; Gallant, JE; Gupta, RK; Hamers, RL; Hosseinipour, MC; Jordan, MR; Kantor, R; Katzenstein, D; Mukui, I; Ndembi, N; Parkin, N; Raizes, E; Rhee, SY; Richman, DD; Rinke de Wit, TF; Schapiro, JM; Schito, M; Shafer, RW; Tang, M; Van Zyl, GU; Wainberg, MA; Wallis, CL; Wensing, AM; Yang, C; Zeh, C | 1 |
| Kumar, S; Rao, PS | 1 |
| Bon, I; Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Manfredi, R; Re, MC; Viale, P | 1 |
| Fox, J; Hamzah, L; Kulasegaram, R; Post, F; Siddiqui, A; Tiraboschi, J | 1 |
| Bravo, I; Cañadas, MP; Clotet, B; García-Rosado, D; Llibre, JM; Moltó, J; Paredes, R; Pérez-Álvarez, N; Santos, JR | 1 |
| Baugh, BP; Coate, B; Dayaram, YK; De La Rosa, G; Overton, ET; Perniciaro, A; Ryan, R; Tebas, P | 1 |
| Back, D; Gibbons, S; Khoo, S; Marzolini, C | 1 |
| Flores-Ruiz, E; Huerta-García, G; Mata-Marín, JA; Peregrino-Bejarano, L; Solórzano-Santos, F; Vazquez-Rosales, JG | 1 |
| Assoumou, L; Benalycherif, A; Cabié, A; Costagliola, D; Duvivier, C; Girard, PM; Joly, V; Lambert-Niclot, S; Landman, R; Marcelin, AG; Peytavin, G; Pialoux, G; Samri, A; Slama, L; Valin, N | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Fletcher, CV; Gonzalez, A; Graham, B; Hazra, R; Jean-Philippe, P; Wiznia, A; Yogev, R | 1 |
| De Paepe, E; Hoetelmans, RM; Kakuda, TN; Lavreys, L; Sekar, V; Stevens, T; Vangeneugden, T; Vanstockem, M | 1 |
| Cattaneo, D; D'Avolio, A; Gervasoni, C; Micheli, V; Milazzo, L; Sollima, S | 1 |
| Berger, M; Bogner, JR; Degen, O; Fätkenheuer, G; Harrer, T; Härter, G; Jensen, B; Jessen, AB; Jessen, H; Jung, N; Kern, WV; Kittner, JM; Knecht, G; Kümmerle, T; Malfertheiner, P; Ranneberg, B; Rockstroh, J; Salzberger, B; Schnaitmann, E; Scholten, S; Schürmann, D; Spinner, CD; Spornraft-Ragaller, P; Stephan, C; Stoehr, A; Ulmer, A; Vogelmann, R | 1 |
| Burger, DM; D'Avolio, A; Di Perri, G; Drenth, JP; Grintjes, K; Kanter, CT; Smolders, EJ; van Crevel, R | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Foca, M; Graham, B; Hazra, R; Jean-Philippe, P; King, J; Wiznia, A; Yogev, R | 1 |
| Baugh, B; Brown, K; Crauwels, HM; Hillewaert, V; Kakuda, TN; Osiyemi, OO; Ryan, B; Verboven, P; Yasin, S; Zorrilla, C | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Gonzalez, A; Graham, B; Hazra, R; Jean-Philippe, P; Larson, KB; Wiznia, A; Yogev, R | 1 |
| Fox, J; Hamzah, L; Jendruleck, I; Kulasegaram, R; Murray, T; Post, F; Teague, A; Tiraboschi, J | 1 |
| Castro-Iglesias, Á; Cid, P; Grandal, M; Margusino, L; Mena, Á; Pedreira, JD; Pernas, B; Pértega, S; Poveda, E; Tabernilla, A | 1 |
| Airoldi, G; Antinori, A; Bini, T; Castagna, A; Colella, E; Gianotti, N; Mancusi, D; Meraviglia, P; Monforte, Ad; Mussini, C; Rusconi, S; Termini, R | 1 |
| Antinori, A; Arribas, JR; Bicer, C; Girard, PM; Hadacek, B; Moecklinghoff, C; Netzle-Sveine, B; Ripamonti, D | 1 |
| Alteri, C; Andreoni, M; Antinori, A; Armenia, D; Bertoli, A; Borghi, V; Ceccherini-Silberstein, F; Cicalini, S; D'Offizi, G; Di Carlo, D; Forbici, F; Giuliani, M; Gori, C; Maffongelli, G; Mussini, C; Nicastri, E; Perno, CF; Pinnetti, C; Santoro, MM; Zaccarelli, M | 1 |
| Heatley, MK; Roberts, B; Yoganathan, K | 1 |
| Castilla, JA; Gonzalvo, MC; Hidalgo-Tenorio, C; Javier, R; Lopez-Ruz, MA; López-Zúñiga, MA; Navas, P; Pasquau, J; Sampedro, A | 1 |
| Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Romero, R | 1 |
| Baldelli, F; Celesia, BM; Focà, E; Galli, L; Gianotti, N; Lazzarin, A; Lo Caputo, S; Maserati, R; Palvarini, L; Ripamonti, D; Sighinolfi, L; Sterrantino, G | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Carpio, F; DeJesus, E; Fusco, G; Fusco, J; Henegar, C; Hsu, R; Lackey, P; Mills, A; Pierone, G; Wohlfeiler, M | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO | 1 |
| Baldin, GM; Capetti, AF; Cattelan, AM; Cenderello, G; Cima, S; Cossu, MV; De Socio, GV; Niero, FP; Riccardi, N; Rizzardini, G; Rusconi, S; Sasset, L; Sterrantino, G | 1 |
| Ascione, T; Boccia, G; Carleo, MA; De Caro, F; Pagliano, P; Tortora, F | 1 |
| Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F | 1 |
| Asensi-Díez, R; Castaño-Carracedo, MA; Del Rio-Valencia, JC; Muñoz-Castillo, I; Yunquera-Romero, L | 1 |
| Luetkehoelter, J; Tseng, AL; Walmsley, SL | 1 |
| Blanco, JR | 1 |
| Bisbal, O; de Lagarde, M; Domínguez, L; Matarranz, M; Rubio, R | 1 |
| Galindo Puerto, MJ | 1 |
| Blanco Arévalo, JL | 1 |
| González-Domenech, CM; Palacios, R; Santos, J | 1 |
| Iribarren, JA | 1 |
| Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; Celesia, BM; Cozzi-Lepri, A; d'Arminio Monforte, A; De Luca, A; Galli, M; Gianotti, N; Mussini, C; Pinnetti, C; Spagnuolo, V | 1 |
| Khoo, S; Owen, A; Roberts, O; Siccardi, M | 1 |
| Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D | 1 |
| Capetti, A; Cattaneo, D; Clementi, E; Cozzi, V; Gervasoni, C; Riva, A; Rizzardini, G | 1 |
| Arduino, G; Ariaudo, A; Bonora, S; Calcagno, A; Carcieri, C; D'Avolio, A; Di Perri, G; Marinaro, L; Pagani, N; Tettoni, MC; Trentini, L | 1 |
| Abdel-Maboud, M; Abushouk, AI; Ahmed, H; Attia, A; Elmaraezy, A; Gadelkarim, M; Ismail, A; Menshawy, A; Menshawy, E; Negida, A | 1 |
| Ashworth, A; Barker, J; Davies, A; Feddy, L; Fedor, I; Ghazi Suliman, MA; Hayes, T; Kosmidis, C; Malagon, I; Ogungbenro, K; Stirling, S; Szabo-Barnes, A | 1 |
| Antoniou, T; Bayoumi, AM; Burchell, AN; Cooper, C; Hogg, RS; Klein, MB; Loutfy, M; Machouf, N; Montaner, JS; Raboud, J; Szadkowski, L; Tsoukas, C; Walmsley, S; Wong, A | 1 |
| Antinori, A; Bonora, S; Carbone, A; Cozzi-Lepri, A; De Luca, A; Di Biagio, A; Di Giambenedetto, S; Gianotti, N; Madeddu, G; Rusconi, S | 1 |
| Angarano, G; Bellacosa, C; Bellazzi, LI; Celesia, BM; Chirianni, A; Cicalini, S; Corsi, P; Grilli, E; Ladisa, N; Leone, A; Maggi, P; Martinelli, C; Maserati, R; Ricci, ED; Sozio, F; Viglietti, R; Volpe, A | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, N; Wainberg, MA | 1 |
| Arya, V; Au, S; Mullick, C; Struble, K; Wagner, C; Zhao, P | 1 |
| Harper, KN | 1 |
| Bartels, H; Battegay, M; Decosterd, L; Marzolini, C | 1 |
| Cory, TJ; Gong, Y; Kumar, S; Li, J; Li, W; Meibohm, B; Midde, NM | 1 |
| Hughes, CA; Phillips, EJ; Seet, J; Tseng, A; Wu, J | 1 |
| Alffenaar, JC; Bierman, WFW; Daskapan, A; de Weerd, DA; Dijkema, D; Kosterink, JGW; Stienstra, Y; van der Werf, TS | 1 |
| Buaben, AO; Burger, DM; Colbers, AP; Freriksen, JJM; Greupink, R; Russel, FGM; Schalkwijk, S | 1 |
| Boesecke, C; Degen, O; Klinker, HHF; Krznaric, I; Kümmerle, T; Schwerdtfeger, C; Spinner, CD; Wolf, E; Zink, A | 1 |
| Espinoza, LA; Gonzales Zamora, JA | 1 |
| Baldin, GM; Barbarini, G; Capetti, AF; Cattelan, AM; Cenderello, G; Cossu, MV; De Socio, GV; Niero, FP; Orofino, G; Riccardi, N; Rizzardini, G; Rusconi, S; Soria, A; Sterrantino, G | 1 |
| Alejos, B; Arribas, JR; Barrufet, P; Cervero, M; Curran, A; Domingo, P; Iribarren, JA; Knobel, H; Lagarde, M; Palacios, R; Payeras, A; Pérez-Valero, I; Pulido, F; Ribera, E; Rivero, A; Rodríguez-Gómez, FJ; Ryan, P; Sanz, J; Téllez, MJ; Yllescas, M | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Joly, V; Landman, R; Marcelin, AG; Perrier, M; Todesco, E; Visseaux, B; Yazdanpanah, Y | 1 |
| Ganase, B; Harrigan, PR; Harris, M; Hull, MW; Montaner, JSG; Watson, B | 1 |
| Bojko, P; Hentrich, M; Jäger, H; Schipek-Voigt, K; Schmid, P; Schulz, S; Stötzer, O | 1 |
| Fulco, PP; Higginson, RT; Kakadiya, PP | 1 |
| Bruno, S; Corrigan, B; Letsie, M; Mthethwa, N; Mukui, I; Mulenga, L; Rakhmanina, N | 1 |
| Chen, JS; DiMeglio, LA; Geffner, ME; Jacobson, D; Jao, J; Karalius, B; McFarland, EJ; Miller, TL; Mirza, A; Patel, K; Silio, M; Van Dyke, RB; Yu, W | 1 |
| Antinori, A; Canovari, B; Colafigli, M; Colangeli, V; D'Arminio Monforte, A; D'Avino, A; De Luca, A; Di Biagio, A; Di Giambenedetto, S; Fantauzzi, A; Francisci, D; Gagliardini, R; Ghisetti, V; Grima, P; Lamonica, S; Latini, A; Lisi, L; Mastroianni, C; Meini, G; Micheli, V; Navarra, P; Orofino, G; Re, MC; Rossetti, B; Rusconi, S; Sterrantino, G; Trezzi, M; Vignale, F; Vullo, V; Zazzi, M | 1 |
| Back, D; Boffito, M; Devitt, E; Else, L; Higgs, C; Jackson, A; Karolia, Z; Khoo, S; Pozniak, A | 1 |
| Assoumou, L; Caby, F; Calin, R; Katlama, C; Lê, MP; Marcelin, AG; Nguyen, T; Peytavin, G; Schneider, L; Seang, S; Soulie, C; Tubiana, R; Valantin, MA | 1 |
| Lundgren, J; Mocroft, A; Ryom, L | 1 |
| Alonso, J; Barber, TJ; Boffito, M; Davies, N; Fortuny, R; Gazzard, B; Imaz, A; Mandalia, S; Niubó, J; Podzamczer, D; Pozniak, A | 1 |
| Bonnal, C; Descamps, D; Desselas, E; Giraud, J; Lariven, S; Le Meur, L; Lê, MP; Lillo-Le-Louet, A; Massias, L; Peytavin, G; Sonneville, R; Tantet, C; Yazdanpanah, Y | 1 |
| Cattaneo, D; Formenti, T; Fossati, A; Gervasoni, C; Meraviglia, P; Minisci, D; Resnati, C | 1 |
| Avettand-Fenoel, V; Cheret, A; Hirt, D; Meyer, L; Morlat, P; Naqvi, A; Pressiat, C; Rouzioux, C; Tran, L; Treluyer, JM; Viard, JP; Zheng, Y | 1 |
| Bastiaans, DET; Burger, DM; Colbers, APH; Geelen, SPM; Roukens, M; van der Flier, M; van Rossum, AMC; Vermont, CL; Visser, EG | 1 |
| Antinori, A; Lazzarin, A; Mancusi, D; Palma, M; Termini, R; Uglietti, A | 1 |
| Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Molina, JM; Nguyen, BY; Rodgers, A; Sax, PE; Sklar, P; Squires, K; Xu, X | 1 |
| Concia, E; Cucchetto, G; Lanzafame, M; Lattuada, E; Nicolè, S; Rigo, F | 1 |
| De Wit, S; Demeester, R; Florence, E; Goffard, JC; Moutschen, M; Piryns, H; Thilakarathne, P; Van Wijngaerden, E; Vandekerckhove, L; Vandercam, B | 1 |
| Araki, T; Gohda, F; Handa, H; Nagano, D; Nakamura, T; Ogawa, Y; Uchiumi, H; Yamamoto, K; Yanagisawa, K | 1 |
| Arzi, RS; Ashkenazi, DL; Augustine, R; Shofti, R; Sosnik, A; Zlobin, V | 1 |
| Bouteloup, V; Calvez, V; Flandre, P; Girard, PM; Grude, M; Izopet, J; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Meynard, JL; Moinot, L; Morand-Joubert, L; Valantin, MA | 1 |
| Chaix, ML; Chevret, S; Delobel, P; Desseaux, K; El Abbassi, EM; Gallien, S; Katlama, C; Madelaine, I; Molina, JM; Peytavin, G; Raffi, F; Saillard, J; Valin, N | 1 |
| Byrn, SR; Mo, H; Nie, H | 1 |
| Bertrand, J; Chaix, ML; Chevret, S; Delobel, P; El Abbassi, EMB; Gallien, S; Katlama, C; Lê, MP; Molina, JM; Peytavin, G; Raffi, F; Saillard, J; Yazdanpanah, Y | 1 |
| Ellis, RJ; Gouaux, B; Letendre, SL; Levine, AJ; Moore, DJ; Soontornniyomkij, B; Soontornniyomkij, V; Umlauf, A | 1 |
| Höring, S; Löffler, B; Pletz, MW; Rößler, S; Schleenvoigt, BT; Weis, S | 1 |
| Alejos, B; Allavena, C; Arribas, JR; Bernardino, JI; de Miguel, R; Esteban-Cantos, A; Gisslén, M; Hoffmann, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Duggan, JM; Sahloff, EG | 1 |
| Brogan, AJ; Davis, AE; Goodwin, B | 1 |
| Chaix, ML; Chevret, S; Delobel, P; Gallien, S; Katlama, C; Lê, MP; Molina, JM; Peytavin, G; Raffi, F; Saillard, J; Yazdanpanah, Y | 1 |
| Antinori, A; Carrara, S; Cozzi Lepri, A; D'arminio Monforte, A; Dentone, C; Di Biagio, A; Fenoglio, D; Filaci, G; Giacometti, A; Lichtner, M; Marchetti, G; Sighinolfi, L | 1 |
| Castro, Á; Cid, P; Dueñas, C; Garcinuño, MÁ; Grande, C; Lorenzo, JF; Margusino, L; Mena, Á; Quiñones, M; Rodríguez-Osorio, I | 1 |
| Bociąga-Jasik, M; Cielniak, I; Firląg Burkacka, E; Gąsiorowski, J; Horban, A; Jabłonowska, E; Kalinowska, A; Piątek, A; Siwak, E; Wójcik-Cichy, K | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Bai, F; Battisti, A; Bavaro, DF; Bezenchek, A; De Luca, A; Di Carlo, D; Di Giambenedetto, S; Gagliardini, R; Giachè, S; Incardona, F; Lo Caputo, S; Pecorari, M; Salomoni, E; Zazzi, M; Zuccalà, P | 1 |
| Best, BM; Burger, DM; Capparelli, E; Colbers, A; Cressey, TR; Greupink, R; Karlsson, MO; Mirochnick, M; Moltó, J; Russel, FGM; Schalkwijk, S; Ter Heine, R | 1 |
| Avramovic, G; Else, LJ; Jackson, V; Khoo, SH; Kuan, KB; Lambert, JS; Lawler, M; Le Blanc, D; McDonald, G; Murtagh, R; Patel, A; Redmond, N | 1 |
| Casado, JL; Fontecha, M; Monsalvo, M; Moreno, A; Rodriguez-Sagrado, MA; Vivancos, MJ | 1 |
| Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW | 1 |
| Borghetti, A; Canovari, B; Ciccullo, A; Colafigli, M; Colangeli, V; De Luca, A; Di Biagio, A; Di Giambenedetto, S; DʼArminio Monforte, A; Francisci, D; Gagliardini, R; Lamonica, S; Latini, A; Mastroianni, C; Mezzaroma, I; Orofino, G; Rossetti, B; Rusconi, S; Sterrantino, G; Trezzi, M; Vignale, F; Vullo, V | 1 |
| Hamid, M; McGowan, M; Meaney, CJ; O'Connor, M; Su, W | 1 |
| Orkin, C | 1 |
| Akpomiemie, G; Arulappan, N; Boyles, T; Chitauri, G; Hill, A; Maharaj, E; Mashabane, N; Moorhouse, M; Qavi, A; Ripin, D; Serenata, C; Sim, JW; Sinxadi, PZ; Sokhela, S; Stacey, S; Venter, WDF; Wallis, C; Wiesner, L | 1 |
| Abdullahi, A; Bonnett, L; Defo, VF; Fokam, J; Geretti, AM; Kouanfack, C; Mafotsing Fopoussi, O; Moudourou, S; Torimiro, J | 1 |
| De Clercq, L; De Spiegelaere, W; Rutsaert, S; Vandekerckhove, L | 1 |
| Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L | 1 |
| Brown, TT; Landay, A; Masters, MC; Miyahara, S; Robertson, K; Taiwo, BO; Vecchio, A | 1 |
| Alejos, B; Arribas, JR; Bernardino, JI; De Miguel, R; Esser, S; Esteban-Cantos, A; Goujard, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Sarmento-Castro, R; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Antinori, A; Barchi, E; Bonfanti, P; Bonora, S; Borghi, V; Cattelan, AM; D'Ettorre, G; Degli Antoni, A; Di Biagio, A; Focà, E; Francisci, D; Limonta, S; Maggiolo, F; Mussini, C; Nozza, S; Roncaglia, E; Rusconi, S; Segala, D | 1 |
| Anglaret, X; Anzian, A; Bado, G; Benalycherif, A; Chaix, ML; Cisse, M; Congo-Ouedraogo, M; de Monteynard, LA; Diallo, I; Diallo, M; Drabo, J; Eholie, SP; Ello, F; Gabassi, A; Gabillard, D; Girard, PM; Karcher, S; Landman, R; Le Carrou, J; Maiga, AI; Messou, E; Minta, DK; Moh, R; Peytavin, G; Sangaré, L; Sawadogo, A; Seydi, M; Toni, TD; Toure-Kane, C; Zoungrana, J | 1 |
| Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Martin, EA; Molina, JM; Rodgers, A; Sax, PE; Sklar, P; Squires, K | 1 |
| Barber, TJ; Spinner, CD | 1 |
| Boffito, M; Bonora, S; Cursley, A; D'Avolio, A; Di Perri, G; Dickinson, L; Fäetkenheuer, G; Gurjar, R; Molina, JM; Owen, A; Pozniak, A; Raffi, F; Richert, L; Stöhr, W; Vandekerckhove, L | 1 |
| Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T | 1 |
| Best, BM; Capparelli, EV; Chakhtoura, N; Eke, AC; Kreitchmann, R; Mirochnick, M; Shapiro, DE; Smith, E; Stek, AM; Wang, J | 1 |
| Ebrahim, I; Maartens, G; McIlleron, H; Orrell, C; Smythe, W; Wiesner, L | 1 |
| Antinori, A; Bonora, S; Castelli, F; Cattelan, AM; Cauda, R; Celesia, BM; Cossu, MV; d'Arminio Monforte, A; Gianotti, N; Gori, A; Mancusi, D; Manzillo, E; Maserati, R; Menzaghi, B; Orofino, G; Ripamonti, D; Rucci, F; Rusconi, S; Santantonio, TA; Savinelli, S; Sterrantino, G; Stingone, C; Termini, R; Uglietti, A; Vergori, A | 1 |
| Bernardino, JI; Casado, JL; Colomer, J; Curran, A; Domingo, P; González-Cordón, A; Llibre, JM; Martínez, E; Navarro, J; Portilla, J; Rial-Crestelo, D; Ribera, E; Vizcarra, P | 1 |
| Antinori, A; Cavellec, M; de Wit, S; Gaultier, A; Jessen, H; Le Thuaut, A; Molina, JM; Ningre, M; Pozniak, A; Raffi, F; Soria, A | 1 |
| Cravedi, P; Degli Antoni, A; Delsante, M; Fiaccadori, E; Gandolfini, I; Maggiore, U; Manenti, L; Peruzzi, L; Riella, LV; Zaza, G | 1 |
| Bagalà, A; Bartiromo, M; Bartoloni, A; Borchi, B; Botta, A; Bresci, S; Cavallo, A; Cirami, C; Cutruzzulà, R; Larti, A; Lugli, G; Tilli, M; Vaglio, A; Xhaferi, B | 1 |
| Costanzo, M; De Giglio, MAR; Roviello, GN | 1 |
| Bernacchia, D; Cattaneo, D; Conti, F; Gervasoni, C; Lupo, A; Merli, S; Pezzati, L; Riva, A; Rusconi, S; Siano, M; Sollima, S | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
| Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A | 1 |
| Anselmi, E; Cavanna, L; Citterio, C; Codeluppi, M; Stroppa, EM; Toscani, I; Zaffignani, E | 1 |
| Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R | 1 |
| Blanch-Lombarte, O; Clotet, B; Jiménez-Moyano, E; Paredes, R; Peña, R; Prado, JG; Santos, JR | 1 |
| Balogh, A; Bidner, H; Boesecke, C; Klinker, HHF; Schneider, J; Spinner, CD; Weidlich, S; Wolf, E; Zink, A | 1 |
| Cipriani, MS; Massabeti, R; Valenti, I | 1 |
| Danzi, GB; Di Tano, G; Gherbesi, E; Loffi, M; Moschini, L; Regazzoni, V | 1 |
| Belkhir, L; Elens, L; Haufroid, V; Stillemans, G; Vandercam, B; Vincent, A | 1 |
| Brígido, LFM; de Miranda, ÉJFP; Juliato, D; Lopes, GISL; Martins, AP; Santos, AMRD; Vidal, JE | 1 |
| Caselli, E; De Giorgi, A; De Giorgio, R; Di Simone, E; Fabbian, F; Greco, S; Manfredini, R; Passaro, A; Zuliani, G | 1 |
| Devanathan, AS; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kashuba, ADM; Kuruc, JD; Margolis, DM; McGee, KS; McKellar, M; Neo, DT; Robertson, K; Schmitz, JL; Sebastian, J; Shaheen, NJ | 1 |
| Alessandrini, AI; Baldi, F; Balletto, E; Barisione, E; Bassetti, M; Beltramini, S; Berruti, M; Briano, F; Bruzzone, B; Camera, M; Da Rin, G; De Maria, A; Delfino, E; Dentone, C; Dettori, S; Di Biagio, A; Dodi, F; Ferrazin, A; Giacobbe, DR; Giacomini, M; Gratarola, A; Icardi, G; Labate, L; Magnasco, L; Mazzarello, G; Mikulska, M; Mirabella, M; Mora, S; Nicolini, LA; Orsi, A; Pelosi, P; Pincino, R; Portunato, F; Rosseti, N; Russo, C; Sasso, E; Schenone, E; Sepulcri, C; Signori, A; Sormani, MP; Taramasso, L; Toscanini, F; Tutino, S; Vena, A | 1 |
| Cauldbeck, H; Elkateb, H; McDonald, T; Niezabitowska, E; Owen, A; Rannard, S; Tatham, LM | 1 |
| Bazzoli, F; Cescon, M; Cristini, F; Dajti, E; Tamanini, G; Tamè, M | 1 |
| Ferrari, SA; Muzzarelli, L; Piconi, S; Rossi, G; Sommaruga, S | 1 |
| Emanuela, C; Francesco, L; Giorgia, G; Pasquale, N; Roberto, P; Sara, D | 1 |
| Hirano, Y; Komatsu, TS; Koyama, YM; Morimoto, G; Ohno, Y; Okimoto, N; Taiji, M | 1 |
| Alvarez Bognar, F; Elion, R; Hwang, C; Martin, EA; Orkin, C; Rockstroh, JK; Sklar, P; Thompson, M; Xu, ZJ | 1 |
| Ballivian, J; Cassetti, I; Cecchini, DM; Huberman, M; Rombini, F; Urueña, A | 1 |
| Blanche, S; Chetty, P; Hufkens, V; Masenya, M; Opsomer, M; Vanveggel, S; Violari, A | 1 |
| Cohen, J; Eckardt, P; Mohan, A; Sherman, EM; Tijmes, S | 1 |
| Dallocchio, RN; De Vito, A; Delogu, G; Dessì, A; Madeddu, G; Serra, PA | 1 |
| Cattaneo, D; Corbellino, M; Cozzi, V; Fusi, M; Gervasoni, C | 1 |
| Boesecke, C; Bührlen, B; Cordes, C; Fischer, F; Heiken, H; Jensen, BE; Krznaric, I; Kümmerle, T; Olliges, E; Ronel, J; Schneider, J; Scholten, S; Spinner, CD; Stellbrink, HJ; Weidlich, S; Wolf, E | 1 |
| Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W | 1 |
| Bellavita, G; Bonzi, L; Buoite Stella, A; Cecotti, L; D Acunto, L; Fabris, M; Furlanis, G; Manganotti, P; Pesavento, V; Sartori, A; Tommasini, V | 1 |
| Chao, CM; Hsueh, PR; Lai, CC | 1 |
| Dengale, S; Lakshman, YD; Mehta, CH; Nayak, UY; Reddy, SC; Shete, S; Vullendula, SKA | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S | 1 |
| Abu Khattab, M; Al Maslamani, M; Al Soub, H; Al-Khal, A; Alibrahim, R; Elmekaty, EZI; Elsayed, A; Eltaib, S; Hassanin, R; Mohamed Ibrahim, MI; Rustom, F | 1 |
| Akpomiemie, G; Christofides, N; Lalla-Edward, S; Machisa, M; Mokgethi, NO | 1 |
| Bungau, SG; Marin, RC; Moleriu, LC; Streinu-Cercel, A | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Byakika-Kibwika, P; Chappell, CA; Fletcher, CV; Jeppson, J; Kaboggoza, J; Kyohairwe, I; Lamorde, M; Mbabazi, L; Musaazi, J; Nakalema, S; Nakijoba, R; Nassiwa, S; Pham, M; Scarsi, KK; Siccardi, M; Walimbwa, SI; Winchester, L | 1 |
| Aebi-Popp, K; Crisinel, PA; Decosterd, L; Duppenthaler, A; Hoesli, I; Kahlert, CR; Martinez De Tejada, B; Marzolini, C; Rauch, A; Saldanha, SA | 1 |
| Chen, W; Deng, M; Lin, J; Lv, X; Shen, L; Shen, P; Zhang, Y | 1 |
| Bellecave, P; Bonnet, F; Cazanave, C; Duffau, P; Hessamfar, M; Lazaro, E; Le Marec, F; Leleux, O; Neau, D; Nyamankolly, E; Perrier, A; Tumiotto, C; Vareil, MO; Wittkop, L | 1 |
| Campisi, J; Desprez, PY; Hughes, JB; Kuehnemann, C; Melov, S; Wiley, CD | 1 |
| Cuéllar-Monreal, MJ; Monte-Boquet, E; Montero, M; Pérez-Huertas, P; Poveda-Andrés, JL; Salavert, M; Solana-Altabella, A | 1 |
| Atkinson, H; Coghlan, H; Edgerton, J; Elsby, R; Hodgson, D; Outteridge, S | 1 |
| Bungau, SG; Marin, RC; Moleriu, RD; Negru, PA; Radu, AF; Tit, DM | 1 |
| Abdalla, S; Coelho, A; Compagnucci, A; Cressey, TR; Hirt, D; Ramos, JT; Riault, Y; Saidi, Y; Tréluyer, JM; Zheng, Y | 1 |
| Bruzzone, B; Castagna, A; Di Biagio, A; Labate, L; Santoro, MM; Spagnuolo, V; Zazzi, M | 1 |
| Avettand-Fenoel, V; Brunet-Cartier, C; Bui, E; Canestri, A; Chabrol, A; Chambrin, V; Delmas, S; Frange, P; Le Chenadec, J; Mandelbrot, L; Marchand, L; Morlat, P; Paul, C; Peretti, D; Peytavin, G; Sibiude, J; Simon-Toulza, C; Tubiana, R; Warszawski, J | 1 |
| Ambe Chenwi, C; Angong Beloumou, G; Dambaya, B; Djupsa Ndjeyep, SC; Fokam, J; Ka'e, AC; Kouanfack, C; Mbopi Keou, FX; Mbouyap, PR; Mossiang, L; Ndjolo, A; Ngoufack Jagni Semengue, E; Nka, AD; Takou, D; Teto, G | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
| Cohen, CE; Garvey, L; Heskin, J; Leung, S; Naous, N; Oddie, PD | 1 |
38 review(s) available for darunavir and ritonavir
| Article | Year |
|---|---|
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antiviral Agents; Aspartic Acid Endopeptidases; Biological Products; Darunavir; Drug Design; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Molecular Mimicry; Molecular Structure; Peptides; Structure-Activity Relationship; Sulfonamides | 2009 |
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Chemoprevention; Drug Design; Drug Discovery; Drug Resistance, Viral; HIV Protease Inhibitors; Humans; Molecular Targeted Therapy; Mutation; Prodrugs; Solubility; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Protease inhibitors].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2005 |
Darunavir (TMC114): a new HIV-1 protease inhibitor.
Topics: Controlled Clinical Trials as Topic; Darunavir; Drug Combinations; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Quality of Life; Ritonavir; Sulfonamides | 2007 |
Clinical pharmacokinetics of darunavir.
Topics: Administration, Oral; Area Under Curve; Biological Availability; Darunavir; HIV Protease Inhibitors; HIV-1; Humans; Molecular Structure; Ritonavir; Sulfonamides | 2007 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Molecular Structure; Ritonavir; Sulfonamides | 2008 |
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viremia | 2008 |
[Safety and tolerability of darunavir].
Topics: Adult; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Lopinavir; Male; Multicenter Studies as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
[Pharmacological interactions with darunavir].
Topics: Anti-HIV Agents; Anti-Infective Agents; Anti-Ulcer Agents; Cardiovascular Agents; Contraceptives, Oral, Hormonal; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Microsomes, Liver; Phosphodiesterase Inhibitors; Ritonavir; Selective Serotonin Reuptake Inhibitors; Sulfonamides | 2008 |
Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Ritonavir; Sulfonamides | 2009 |
Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.
Topics: Adolescent; Adult; Child; Clinical Trials, Phase II as Topic; Darunavir; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Synergism; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides | 2010 |
Protease inhibitor monotherapy.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2011 |
A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cost-Benefit Analysis; Darunavir; Drug Costs; HIV; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Ritonavir; Standard of Care; Sulfonamides | 2010 |
Pharmacoeconomics of darunavir.
Topics: Cost-Benefit Analysis; Darunavir; Disease Progression; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Quality of Life; Quality-Adjusted Life Years; Ritonavir; Sulfonamides | 2011 |
Darunavir: an effective protease inhibitor for HIV-infected patients.
Topics: Darunavir; Drug Administration Routes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication | 2011 |
Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.
Topics: Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Evidence-Based Medicine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Maintenance Chemotherapy; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2012 |
Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; HIV Infections; HIV-1; Humans; Odds Ratio; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Gastric Bypass; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir | 2014 |
Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lipids; Male; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Ritonavir; Time Factors; Treatment Outcome | 2015 |
Darunavir/cobicistat once daily for the treatment of HIV.
Topics: Clinical Trials as Topic; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Treatment Outcome | 2015 |
Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Topics: Atazanavir Sulfate; Cerebrospinal Fluid; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome | 2016 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
[Rescue therapy with darunavir for treatment-experienced HIV-infected patients].
Topics: Clinical Trials as Topic; Darunavir; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Treatment Outcome; Viral Load | 2016 |
[Long-term safety and effectiveness of darunavir].
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Treatment Outcome | 2016 |
[Darunavir as initial therapy for human immunodeficiency virus infection and as a strategy for switching regimen not motivated by virological failure].
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; HIV Infections; Humans; Ritonavir; Viral Load | 2016 |
[Pharmacological aspects of darunavir/cobicistat].
Topics: Cobicistat; Darunavir; Drug Combinations; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2016 |
Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2017 |
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; Quinolones; Ritonavir | 2017 |
Contemporary protease inhibitors and cardiovascular risk.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Risk Assessment; Ritonavir | 2018 |
Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load | 2018 |
Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2018 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Current treatment of COVID-19 in renal patients: hope or hype?
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal; Cobicistat; Coronavirus Infections; COVID-19; Darunavir; Drug Combinations; Humans; Kidney; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ritonavir | 2020 |
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Carbamates; Cobicistat; COVID-19 Drug Treatment; Darunavir; Dibenzothiepins; Drug Combinations; Drug Therapy, Combination; Humans; Imidazoles; Indoles; Iran; Lopinavir; Morpholines; Pyrazines; Pyridones; Pyrrolidines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Triazines; Valine | 2021 |
Drug-induced liver injury secondary to increased levonorgestrel exposure in a patient taking ritonavir.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Darunavir; Female; HIV Infections; Humans; Levonorgestrel; Ritonavir; Tenofovir | 2023 |
165 trial(s) available for darunavir and ritonavir
| Article | Year |
|---|---|
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2005 |
Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Ulcer Agents; Antiviral Agents; Area Under Curve; Darunavir; Drug Interactions; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Ranitidine; Ritonavir; Sulfonamides | 2007 |
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2007 |
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Darunavir; Drug Combinations; Fasting; Female; Food-Drug Interactions; Half-Life; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Ritonavir; Sulfonamides | 2007 |
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Topics: Adult; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2007 |
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Data Interpretation, Statistical; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Predictive Value of Tests; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Pyridines; Pyrones; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Ritonavir; RNA, Viral; Statistics as Topic; Sulfonamides; Time Factors; Viral Load | 2007 |
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
Topics: Adult; Cross-Over Studies; Darunavir; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reference Values; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2007 |
Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Seronegativity; Humans; Middle Aged; Ritonavir; Saquinavir; Sulfonamides | 2007 |
Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Chromatography, High Pressure Liquid; Clarithromycin; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Combinations; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Time Factors | 2008 |
Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome | 2008 |
Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Darunavir; Drug Administration Schedule; Drug Interactions; HIV Protease Inhibitors; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Ritonavir; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Weight Gain | 2008 |
Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
Topics: Adolescent; Adult; Contraceptives, Oral; Cross-Over Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Ethinyl Estradiol; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Norethindrone; Ritonavir; Sulfonamides | 2008 |
Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
Topics: Adolescent; Adult; Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pyridines; Pyrones; Quinolones; Ritonavir; Sulfonamides | 2008 |
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Peptide Fragments; Ritonavir; Sulfonamides; Treatment Outcome | 2008 |
Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
Topics: Adult; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation, Missense; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
[Darunavir in treatment-naïve patients. The ARTEMIS study].
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2008 |
[Darunavir as first-line therapy. The TITAN study].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Darunavir; Diarrhea; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prognosis; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Protease Inhibitors; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Topics: Adolescent; Adult; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fasting; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Sulfonamides; Triglycerides; Young Adult | 2009 |
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Viral Load | 2009 |
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
Topics: Adult; Algorithms; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Logistic Models; Lopinavir; Male; Mutation; Pyrimidinones; Ritonavir; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.
Topics: Adult; Cross-Over Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
Topics: Adolescent; Child; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Patient Compliance; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
Topics: Anti-HIV Agents; Darunavir; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Ritonavir; Sulfonamides | 2009 |
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Immunosuppression Therapy; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2010 |
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; United States; Viral Load | 2010 |
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pyridines; Pyrones; Quinolones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Topics: Adult; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver Diseases; Male; Middle Aged; Ritonavir; Sulfonamides | 2010 |
Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ritonavir; Sulfonamides | 2010 |
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Topics: Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Pilot Projects; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome | 2010 |
Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Therapy, Combination; Female; Gene Expression Regulation; HIV Seronegativity; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Darunavir; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Male; Methadone; Middle Aged; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Ritonavir; Sulfonamides | 2011 |
The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Darunavir; Drug Combinations; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Sulfonamides; Young Adult | 2011 |
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
Topics: Adult; Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Medication Adherence; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.
Topics: Adolescent; Adult; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Rifabutin; Ritonavir; Sulfonamides; Young Adult | 2010 |
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2010 |
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.
Topics: Darunavir; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Male; Plasma; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Semen; Sulfonamides | 2010 |
Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
Topics: Adult; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Mutation; Ritonavir; Sex Factors; Sulfonamides; Viral Load; Young Adult | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Darunavir; Drug Interactions; Echinacea; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Plant Extracts; Ritonavir; Sulfonamides | 2011 |
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Protease; HIV Reverse Transcriptase; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pilot Projects; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
Topics: Adult; Darunavir; Female; HIV Infections; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides | 2011 |
Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Costs; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2010 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Organophosphonates; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2011 |
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2011 |
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
Topics: Adolescent; Adult; Cyclohexanes; Darunavir; Drug Interactions; Female; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Young Adult | 2011 |
Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.
Topics: Adult; Blood Glucose; Body Image; Body Size; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Lipids; Male; Middle Aged; Ritonavir; Sex Factors; Sulfonamides; Treatment Outcome | 2011 |
96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Europe; Female; HIV Infections; Humans; Male; Nucleosides; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure | 2011 |
Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers.
Topics: Adult; Blood Coagulation; Blood Coagulation Factors; Darunavir; Drug Therapy, Combination; Female; Fibrinolysis; HIV Protease Inhibitors; Humans; Male; Middle Aged; Platelet Aggregation; Prospective Studies; Pyridines; Pyrones; Ritonavir; Sulfonamides | 2011 |
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Darunavir; Female; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Sulfonamides; Young Adult | 2011 |
Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cross-Over Studies; Darunavir; Drug Combinations; Drug Interactions; Female; Fluorobenzenes; Half-Life; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Clearance Rate; Middle Aged; Pyrimidines; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triglycerides; Young Adult | 2012 |
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Odds Ratio; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2011 |
Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.
Topics: Adult; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Patient Compliance; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2011 |
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Young Adult | 2011 |
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
Topics: Adult; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2012 |
Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Canada; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV-1; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Nitriles; Pyridazines; Pyrimidines; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; Viral Load; Young Adult | 2012 |
Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.
Topics: Anti-HIV Agents; Area Under Curve; Buprenorphine; Carbamates; Darunavir; Drug Interactions; Female; Furans; Half-Life; History, 16th Century; History, 17th Century; Humans; Male; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides | 2012 |
Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Prospective Studies; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2012 |
Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.
Topics: Adult; Cholesterol; Darunavir; Drug Interactions; Female; Haplotypes; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Genetic; Pravastatin; Ritonavir; Sulfonamides; Triglycerides | 2012 |
Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Protease Inhibitors; HIV-1; Humans; Male; Nitriles; North America; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sex Distribution; Sex Factors; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Darunavir; Deoxyguanine Nucleotides; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2012 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2012 |
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Atazanavir Sulfate; Biomarkers; CD4 Lymphocyte Count; Darunavir; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Female; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Surveys and Questionnaires; Treatment Outcome; Viral Load | 2012 |
Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.
Topics: Adult; Body Fat Distribution; Darunavir; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2012 |
Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Administration Schedule; HIV Infections; Humans; Male; Middle Aged; Ritonavir; Silybum marianum; Silymarin; Sulfonamides | 2012 |
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.
Topics: Adult; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Multidrug Resistance-Associated Protein 2; Polymorphism, Single Nucleotide; Ritonavir; Sulfonamides | 2012 |
Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.
Topics: Adult; Darunavir; DNA, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load; Viremia | 2012 |
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2013 |
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Protease Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2013 |
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Female; Hepacivirus; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Pyridines; Ritonavir; Sulfonamides; Young Adult | 2013 |
Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biological Transport; Confidence Intervals; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Incidental Findings; Male; Membrane Transport Proteins; Middle Aged; Ritonavir; Sulfonamides; Young Adult | 2012 |
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).
Topics: Adult; Age Factors; Cohort Studies; Darunavir; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Internet; Italy; Male; Middle Aged; Prospective Studies; Ritonavir; Sulfonamides; Survival Analysis; Time Factors; Viral Load | 2013 |
Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Cross-Over Studies; Darunavir; Drug Interactions; Ethanolamines; Fluorenes; Healthy Volunteers; HIV; HIV Infections; Humans; Lumefantrine; Malaria; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides | 2013 |
Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Ritonavir; Sulfonamides; Viral Load; Young Adult | 2013 |
Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Models, Biological; Organic Anion Transporters; Polymorphism, Single Nucleotide; Ritonavir; Sulfonamides | 2013 |
Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Beclomethasone; Darunavir; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Young Adult | 2013 |
Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2013 |
Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
Topics: Adolescent; Adult; Darunavir; Drug Administration Schedule; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Sulfonamides; Young Adult | 2014 |
Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2013 |
Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Body Fat Distribution; Bone Density; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome | 2014 |
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Spain; Sulfonamides | 2014 |
Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
Topics: Adult; Biological Availability; Carbamates; Cobicistat; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Combinations; Female; Healthy Volunteers; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Thiazoles; Young Adult | 2014 |
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Proteins; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Neopterin; Oligopeptides; Protein Binding; Pyridines; Ritonavir; RNA, Viral; Sulfonamides | 2014 |
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-HIV Agents; Creatinine; Darunavir; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Serum Albumin; Sulfonamides; Treatment Outcome; Young Adult | 2014 |
Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers.
Topics: Administration, Oral; Adolescent; Adult; Darunavir; Female; Healthy Volunteers; Humans; Male; Middle Aged; Quinolines; Ritonavir; Sulfonamides; Young Adult | 2014 |
Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Cytokines; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Lopinavir; Male; Middle Aged; Ritonavir; Sulfonamides; Viremia | 2014 |
[Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2014 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Leucine; Male; Middle Aged; Oligopeptides; Organophosphonates; Proline; Protease Inhibitors; Quinolines; Ritonavir; Sulfonamides; Tenofovir; Thiazoles; Young Adult | 2014 |
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Darunavir; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2014 |
Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Half-Life; Healthy Volunteers; Humans; Least-Squares Analysis; Male; Metabolic Clearance Rate; Middle Aged; Postprandial Period; Ritonavir; Sulfonamides; Tablets; Therapeutic Equivalency; Young Adult | 2014 |
Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines; Ritonavir; Sulfonamides; Young Adult | 2014 |
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Topics: Adolescent; Anemia; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Nausea; Neutropenia; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Time Factors; Viral Load; Vomiting; Zidovudine | 2014 |
No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Nucleosides; Ritonavir; RNA, Viral; Sulfonamides; Telomerase; Telomere | 2014 |
The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Topics: Adult; Aged; Anti-HIV Agents; Body Fat Distribution; Bone Density; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2015 |
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
Topics: CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Male; Meta-Analysis as Topic; Middle Aged; Nitriles; Odds Ratio; Pyridazines; Pyrimidines; Ritonavir; Spain; Sulfonamides; Switzerland; United Kingdom; Viral Load | 2015 |
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Chromatography, Liquid; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Plasma; Ritonavir; Tandem Mass Spectrometry; Viral Load; Viremia; Young Adult | 2015 |
[Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection].
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viral Load | 2014 |
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial.
Topics: Anti-HIV Agents; Child; Child, Preschool; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Ritonavir | 2015 |
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Raltegravir Potassium; Ritonavir | 2015 |
Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Retreatment; Ritonavir; Treatment Outcome; Viral Load | 2015 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy | 2015 |
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Topics: Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome; Viral Load | 2015 |
Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).
Topics: Adult; Anti-HIV Agents; Bone and Bones; Bone Density; Calcifediol; Darunavir; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Kidney; Male; Middle Aged; Ritonavir; Vitamin D | 2016 |
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; CD4 Lymphocyte Count; Comorbidity; Darunavir; Drug Therapy, Combination; Emtricitabine; Europe; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Osteopetrosis; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2015 |
Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cerebrospinal Fluid; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Prospective Studies; Ritonavir; Semen; Viral Load; Young Adult | 2016 |
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Ritonavir; Viral Load; Young Adult | 2016 |
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomiz
Topics: Adult; Africa; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nucleosides; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
Topics: Adolescent; Darunavir; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Young Adult | 2017 |
Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Darunavir; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; HIV Protease Inhibitors; Humans; Male; Metabolic Clearance Rate; Middle Aged; Netherlands; Pharmaceutical Solutions; Postprandial Period; Ritonavir; Tablets; Young Adult | 2014 |
PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Darunavir; Female; Germany; Humans; Male; Post-Exposure Prophylaxis; Prospective Studies; Ritonavir; Treatment Outcome; Withholding Treatment | 2016 |
Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
Topics: Adolescent; Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Darunavir; Female; HIV Infections; Humans; Plasma; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Tandem Mass Spectrometry; Young Adult | 2016 |
Short Communication: The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study.
Topics: Adult; Anti-HIV Agents; Cognition; Darunavir; Drug Substitution; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Male; Middle Aged; Quality of Life; Ritonavir; Sleep | 2016 |
Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2017 |
Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir | 2017 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Anti-Retroviral Agents; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Tandem Mass Spectrometry | 2017 |
Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Plasma; Prospective Studies; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome | 2017 |
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppressi
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Therapy Management; Middle Aged; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2017 |
CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; Central Nervous System; Cognition; Darunavir; Drug Therapy, Combination; Executive Function; Female; Ferritins; HIV Infections; HIV-1; Humans; Magnetic Resonance Imaging; Male; Maraviroc; Middle Aged; Neopterin; Pilot Projects; Psychomotor Performance; Ritonavir; S100 Calcium Binding Protein beta Subunit | 2018 |
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Models, Statistical; Plasma; Raltegravir Potassium; Ritonavir; Viral Load; Young Adult | 2018 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2018 |
Darunavir concentration in PBMCs may be a better indicator of drug exposure in HIV patients.
Topics: Cell Line, Tumor; Darunavir; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Ritonavir | 2018 |
Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Data Interpretation, Statistical; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2018 |
Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2018 |
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Topics: Adult; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Plasma; Reverse Transcriptase Inhibitors; Ritonavir; Semen; Therapeutic Equivalency | 2018 |
Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; HIV-1; Humans; Male; Models, Economic; Raltegravir Potassium; Ritonavir; United States | 2018 |
Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.
Topics: Adult; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Semen; Tissue Distribution; Virus Shedding | 2019 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult | 2019 |
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Disease Progression; Drug Substitution; Female; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Maraviroc; Middle Aged; Ritonavir | 2019 |
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Treatment Outcome; Viral Load | 2019 |
An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cameroon; Darunavir; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2019 |
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2019 |
Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Biomarkers; Darunavir; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Male; Maraviroc; Ritonavir; Tenofovir | 2020 |
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Cross-Sectional Studies; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Telomere; Tenofovir | 2019 |
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Delayed Diagnosis; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2019 |
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult | 2020 |
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001
Topics: Adult; Anti-HIV Agents; Constitutive Androstane Receptor; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2020 |
Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Rifampin; Ritonavir | 2020 |
Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study.
Topics: Anti-HIV Agents; Darunavir; Emtricitabine; Follow-Up Studies; HIV Infections; HIV-1; Humans; Retrospective Studies; Ritonavir; Viral Load | 2020 |
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.
Topics: Anti-HIV Agents; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Quality of Life; Ritonavir; Viral Load | 2022 |
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine | 2022 |
Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Pyridones; Ritonavir | 2023 |
Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study.
Topics: Anti-HIV Agents; Darunavir; Female; HIV Infections; Humans; Infant, Newborn; Pregnancy; Ritonavir; Treatment Outcome; Viral Load | 2023 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
280 other study(ies) available for darunavir and ritonavir
| Article | Year |
|---|---|
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles | 2005 |
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides | 2006 |
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Molecular Structure; Protein Conformation; Protein Structure, Tertiary; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2006 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage | 2008 |
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Topics: Antiviral Agents; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Ethers, Cyclic; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Ligands; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Polyesters; Stereoisomerism; Structure-Activity Relationship; T-Lymphocytes; Water | 2008 |
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides | 2009 |
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.
Topics: Animals; Binding Sites; Biological Availability; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Crystallography, X-Ray; Dipeptides; Dogs; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Hyperlipidemias; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Mutation; Putrescine; Pyridines; Rats; Rats, Gunn; Stereoisomerism; Structure-Activity Relationship | 2009 |
HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Topics: Alcohols; Antiviral Agents; Crystallography, X-Ray; HIV Protease; HIV Protease Inhibitors; HIV-1; Inhibitory Concentration 50; Molecular Mimicry; Mutation, Missense | 2010 |
Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.
Topics: Animals; Antimalarials; Darunavir; Erythrocytes; HIV Protease Inhibitors; Humans; Life Cycle Stages; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyridines; Pyrones; Sulfonamides | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Failure; Viral Load | 2006 |
FDA clears HIV drug for patients with resistant virus.
Topics: Darunavir; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration | 2006 |
Darunavir (Prezista) for HIV infection.
Topics: Antiretroviral Therapy, Highly Active; Biological Availability; Blood Proteins; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Approval; Drug Interactions; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Peptide Fragments; Protein Binding; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Tablets; Time Factors; United States; Viral Load | 2006 |
TMC114 approved for resistant patients.
Topics: Darunavir; Drug Approval; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration | 2006 |
XVI International AIDS Conference: Part 2.
Topics: Acquired Immunodeficiency Syndrome; CCR5 Receptor Antagonists; Clinical Trials as Topic; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Ritonavir; Salvage Therapy; Sulfonamides | 2006 |
Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
Topics: Darunavir; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Peptide Fragments; Ritonavir; Sulfonamides | 2007 |
Darunavir: promising initial results.
Topics: Clinical Trials as Topic; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides | 2007 |
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
Topics: Carbamates; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Viral Load | 2007 |
48-week study results show DRV's staying power.
Topics: Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Viral Load | 2007 |
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Topics: Adult; Anti-Retroviral Agents; Area Under Curve; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2007 |
Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Seronegativity; Humans; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Volunteers | 2007 |
Predicting HIV care costs using CD4 counts from clinical trials.
Topics: Adult; Alabama; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cohort Studies; Cost of Illness; Cost-Benefit Analysis; Darunavir; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Multivariate Analysis; Primary Health Care; Ritonavir; Student Health Services; Sulfonamides | 2007 |
Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
Topics: Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Phenotype; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2007 |
Relative antiviral efficacy should not be inferred from cross-trial comparisons.
Topics: Cross-Over Studies; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Pyridines; Pyrones; Ritonavir; Sulfonamides; Treatment Outcome | 2007 |
Darunavir phase 3 study data released.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Dog model with implanted pump to test boosters for antiretroviral medication.
Topics: Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Data Interpretation, Statistical; Dogs; Drug Resistance, Viral; Drug Synergism; HIV Protease Inhibitors; Infusion Pumps, Implantable; Male; Ritonavir; Sulfonamides | 2008 |
Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome | 2008 |
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Topics: Animals; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Lipodystrophy; Lopinavir; Membrane Proteins; Metabolic Syndrome; Metalloendopeptidases; Mice; Mice, Knockout; Nuclear Proteins; Protein Precursors; Protein Processing, Post-Translational; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Phenotype; Ritonavir; Sequence Analysis, DNA; Sulfonamides; Treatment Outcome | 2008 |
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Topics: Darunavir; Drug Resistance, Viral; Genes, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Prospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Time Factors | 2008 |
Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.
Topics: Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Sulfonamides | 2008 |
Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir.
Topics: Darunavir; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; Sulfonamides; Virus Replication | 2008 |
Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects.
Topics: Adult; Chromatography, High Pressure Liquid; Darunavir; Dose-Response Relationship, Drug; Feces; HIV Protease Inhibitors; Humans; Male; Middle Aged; Reference Values; Ritonavir; Sulfonamides; Tandem Mass Spectrometry | 2009 |
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
Topics: Amino Acid Substitution; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation, Missense; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Transplacental passage of ritonavir-boosted darunavir in two pregnant women.
Topics: Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infectious Disease Transmission, Vertical; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Sulfonamides | 2009 |
Darunavir now approved for use in treatment-naive patients.
Topics: Darunavir; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; United States | 2008 |
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.
Topics: Adult; Chromatography, Liquid; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Mass Spectrometry; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.
Topics: Adult; Anti-Retroviral Agents; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Protease Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides; Tacrolimus | 2009 |
Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.
Topics: Adolescent; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.
Topics: Chromatography, High Pressure Liquid; Darunavir; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry | 2009 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes.
Topics: Animals; Bile Acids and Salts; Biological Transport; Darunavir; Dogs; Dosage Forms; Female; Fluoresceins; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Liver; Male; Middle Aged; Rats; Rats, Wistar; Ritonavir; Species Specificity; Sulfonamides; Sus scrofa | 2010 |
Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Enfuvirtide; Female; Fingers; HIV Envelope Protein gp41; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Middle Aged; Needlestick Injuries; Occupational Diseases; Organophosphonates; Peptide Fragments; Post-Exposure Prophylaxis; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.
Topics: Animals; Atazanavir Sulfate; Carnitine O-Palmitoyltransferase; CD36 Antigens; Cell Line; Darunavir; Dose-Response Relationship, Drug; Fatty Acid Transport Proteins; Fatty Acids; HIV Protease Inhibitors; Humans; Lopinavir; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Oligopeptides; Oxidation-Reduction; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides | 2010 |
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.
Topics: Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; RNA, Viral; Sulfonamides; Young Adult | 2010 |
Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Interactions; Female; Healthy Volunteers; Humans; Indinavir; Male; Plasma; Ritonavir; Sulfonamides; Young Adult | 2010 |
Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in t
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Viral Load | 2010 |
Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Darunavir; HIV Protease Inhibitors; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Mice; Mice, Knockout; Ritonavir; Sulfonamides | 2010 |
Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
Topics: Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Intestinal Absorption; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Salvage Therapy; Sulfonamides | 2010 |
The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Darunavir; Duodenum; Garlic; Hep G2 Cells; Herb-Drug Interactions; HIV Protease Inhibitors; Humans; Liver; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Plant Extracts; Rats; Rats, Wistar; Ritonavir; Saquinavir; Sulfonamides | 2010 |
Neither ritonavir nor darunavir affect cell surface expression of tetherin or Vpu-mediated tetherin down-modulation.
Topics: Cell Membrane; Darunavir; Flow Cytometry; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Protein Transport; Ritonavir; Sulfonamides; Viral Regulatory and Accessory Proteins | 2010 |
Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; Humans; Male; Middle Aged; Plasma; Prospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Darunavir; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation, Missense; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Ritonavir; Sequence Analysis, DNA; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
Topics: Adolescent; Adult; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Young Adult | 2010 |
Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Cytochrome P-450 Enzyme Inhibitors; Darunavir; Depression; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; HIV Infections; HIV Protease Inhibitors; Humans; Male; Piperazines; Quinolones; Ritonavir; Sulfonamides; Thiophenes | 2010 |
HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cytochrome P-450 CYP3A; Darunavir; Dietary Supplements; Drug Interactions; Enterocytes; Garlic; HIV Protease Inhibitors; Humans; Intestinal Absorption; Intestinal Mucosa; Jejunum; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Plant Extracts; Rats; Rats, Wistar; Ritonavir; Saquinavir; Sulfonamides | 2010 |
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load | 2011 |
Darunavir/ritonavir monotherapy in clinical practice.
Topics: Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2011 |
Changes in cerebral function parameters in HIV type 1-infected subjects switching to darunavir/ritonavir either as monotherapy or with nucleoside analogues.
Topics: Adult; Anti-HIV Agents; Brain; Brain Diseases, Metabolic; Darunavir; Female; HIV Infections; Humans; London; Male; Nucleosides; Prospective Studies; Ritonavir; Sulfonamides | 2011 |
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.
Topics: Adult; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cost-Benefit Analysis; Darunavir; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; United States; Young Adult | 2010 |
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Markov Chains; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Sweden; United Kingdom | 2010 |
US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Disease Progression; Drug Resistance; Female; Health Care Costs; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; Time Factors; United States; Viral Load; Young Adult | 2010 |
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Topics: Adult; Antiretroviral Therapy, Highly Active; Belgium; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Darunavir; Drug Resistance, Viral; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Lopinavir; Male; Markov Chains; Multicenter Studies as Topic; Pyrimidinones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Sweden; United Kingdom; Viral Load | 2010 |
Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
Topics: Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Darunavir; Drug Costs; Europe; Health Care Costs; HIV; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; United States; Young Adult | 2010 |
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.
Topics: Darunavir; Fusion Proteins, gag-pol; HIV Protease Inhibitors; HIV-1; Mutation; Ritonavir; Sulfonamides | 2011 |
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Typing; Mutation; Organophosphonates; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Virus Replication | 2011 |
Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.
Topics: Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
Topics: Anti-HIV Agents; Darunavir; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Peptide Fragments; Pyridines; Pyrones; Ritonavir; Sulfonamides | 2011 |
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
Topics: Algorithms; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Predictive Value of Tests; Ritonavir; Sulfonamides; Treatment Outcome | 2011 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
[Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].
Topics: Abscess; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Axilla; Clarithromycin; Darunavir; Dideoxynucleosides; Enfuvirtide; Ethambutol; HIV Envelope Protein gp41; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Isoniazid; Lamivudine; Lymph Node Excision; Lymphadenitis; Male; Mycobacterium avium-intracellulare Infection; Peptide Fragments; Pyrazinamide; Rifampin; Ritonavir; Streptomycin; Sulfonamides | 2011 |
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2011 |
Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients.
Topics: Adult; Algorithms; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure | 2012 |
[Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].
Topics: Adult; Anti-HIV Agents; Brain Edema; Darunavir; Diagnosis, Differential; Dideoxynucleosides; Emergencies; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Hypertension, Malignant; Hypertensive Encephalopathy; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Nitriles; Posterior Leukoencephalopathy Syndrome; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tomography, X-Ray Computed; Toxoplasmosis, Cerebral | 2012 |
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Darunavir; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Triazoles | 2012 |
Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
Topics: Adult; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Pilot Projects; Retrospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Azo Compounds; Darunavir; Glucose; Glycerol; HIV Protease Inhibitors; Lactic Acid; Lipolysis; Mice; Ritonavir; Staining and Labeling; Sulfonamides | 2012 |
Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain.
Topics: Antiretroviral Therapy, Highly Active; Budgets; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Spain; Sulfonamides | 2012 |
Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Cell Differentiation; Cells, Cultured; Darunavir; HIV Protease Inhibitors; Humans; Insulin Resistance; Lipolysis; Lopinavir; Mice; Mitochondria; Oligopeptides; Pyridines; Reactive Oxygen Species; Ritonavir; Sulfonamides | 2012 |
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Topics: Adult; Darunavir; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides | 2012 |
No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Genotype; HIV Protease Inhibitors; Humans; Nucleosides; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viral Load | 2012 |
Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Ritonavir; RNA, Viral; Selection, Genetic; Sulfonamides; Treatment Failure; Viral Load | 2012 |
Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; C-Reactive Protein; Darunavir; Female; Hepatitis C; HIV Infections; Humans; Interleukin-6; Male; Ritonavir; Sulfonamides; Time Factors | 2012 |
Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nervous System Diseases; Ritonavir; Sulfonamides | 2012 |
Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.
Topics: Adult; Anti-HIV Agents; Darunavir; Human Experimentation; Humans; Male; Nitriles; Plasma; Pyridazines; Pyrimidines; Rectum; Ritonavir; Semen; Sulfonamides; Young Adult | 2012 |
Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.
Topics: Adult; Cohort Studies; Darunavir; Fasting; Genotyping Techniques; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipid Metabolism; Male; Middle Aged; Retrospective Studies; Ritonavir; Safety; Sulfonamides | 2012 |
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia | 2012 |
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
Topics: Anti-HIV Agents; Blood Glucose; Cyclohexanes; Darunavir; Fasting; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Insulin; Insulin Resistance; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome; Triazoles; Viral Load | 2012 |
Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy.
Topics: Adult; Anti-HIV Agents; Cerebrospinal Fluid; Darunavir; Female; HIV Infections; Humans; Male; Ritonavir; Sulfonamides | 2012 |
Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥7 years.
Topics: Adolescent; Area Under Curve; Asian People; Body Weight; Child; Cohort Studies; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Metabolic Clearance Rate; Ritonavir; Sulfonamides; Thailand; Time Factors | 2012 |
Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient.
Topics: Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Citalopram; Coinfection; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Darunavir; Depression; Drug Interactions; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Middle Aged; Polymorphism, Single Nucleotide; Ritonavir; Serotonin Syndrome; Sulfonamides | 2012 |
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; Half-Life; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles | 2013 |
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Topics: Amino Acid Sequence; Atazanavir Sulfate; Binding Sites; Carbamates; Cell Line, Tumor; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Lopinavir; Molecular Docking Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Pyridines; Ritonavir; Structure-Activity Relationship; Sulfonamides; T-Lymphocytes; Virus Replication | 2013 |
Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Viral Load | 2013 |
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Topics: Alkynes; Anti-Retroviral Agents; Antidepressive Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Darunavir; Drug Interactions; Humans; Models, Biological; Oligopeptides; Pyridines; Ritonavir; Sulfonamides | 2013 |
Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy.
Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; Carbamates; CD4 Lymphocyte Count; Darunavir; Dyslipidemias; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolome; Middle Aged; Organophosphates; Prospective Studies; Protease Inhibitors; Ritonavir; Sulfonamides; White People | 2013 |
Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.
Topics: Adult; Anti-HIV Agents; Biomarkers; Darunavir; Female; HIV Infections; Humans; Immunophenotyping; Lymphocyte Activation; Male; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; T-Lymphocytes; Viral Load | 2013 |
Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Darunavir; Drug Combinations; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Models, Economic; Prognosis; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey.
Topics: Adult; Aged; Clinical Trials as Topic; Cross-Sectional Studies; Darunavir; Female; Gender Identity; Health Care Surveys; HIV Infections; HIV Protease Inhibitors; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Puerto Rico; Racial Groups; Ritonavir; Sulfonamides; Surveys and Questionnaires; Treatment Outcome; United States; Viral Load | 2013 |
Efficacy of a reduced dose of darunavir/ritonavir in a small cohort of antiretroviral-naïve HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir; Viral Load | 2013 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Pilot Projects; Ritonavir; RNA Stability; RNA, Viral; Sulfonamides; Treatment Outcome; Triazoles; Viral Load | 2013 |
Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy.
Topics: Adult; AIDS Dementia Complex; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Neuropsychological Tests; Ritonavir; Sulfonamides; Viral Load | 2013 |
Iatrogenic Cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir.
Topics: Cushing Syndrome; Darunavir; Drug Interactions; Female; Glucocorticoids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Iatrogenic Disease; Injections, Intra-Articular; Middle Aged; Ritonavir; Shoulder Pain; Sulfonamides; Treatment Outcome; Triamcinolone | 2013 |
Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Darunavir; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Time Factors; Young Adult | 2013 |
Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Proportional Hazards Models; Pyridines; Retrospective Studies; Ritonavir; Sulfonamides | 2013 |
Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
Topics: Adult; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; United States; Viral Load | 2014 |
Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.
Topics: Adult; Cohort Studies; Darunavir; DNA, Viral; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Prospective Studies; Proviruses; Real-Time Polymerase Chain Reaction; Ritonavir; Sulfonamides; Viral Load; Viremia | 2014 |
Immune activation throughout a boosted darunavir monotherapy simplification strategy.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Darunavir; Female; Fibrin Fibrinogen Degradation Products; HIV Infections; HIV-1; Humans; Immunologic Memory; Immunophenotyping; Male; Middle Aged; Prospective Studies; Ritonavir; Sulfonamides; T-Lymphocyte Subsets; Treatment Outcome | 2014 |
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Maintenance Chemotherapy; Male; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2014 |
Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Retreatment; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2014 |
Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus.
Topics: Ankle Fractures; Anticoagulants; Darunavir; Drug Interactions; Gastrointestinal Hemorrhage; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Morpholines; Ritonavir; Rivaroxaban; Sulfonamides; Thiophenes | 2014 |
Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting.
Topics: Adult; Darunavir; Drug Combinations; Exanthema; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Ritonavir; Sulfonamides | 2014 |
Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Cellular Senescence; Darunavir; Drug Synergism; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lopinavir; Nitric Oxide; Oligopeptides; Oxidative Stress; Pravastatin; Pyridines; Ritonavir; Sulfonamides | 2014 |
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles | 2014 |
Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.
Topics: Atazanavir Sulfate; Darunavir; HIV Protease Inhibitors; Humans; Oligopeptides; Plasma; Pyridines; Ritonavir; Sulfonamides | 2014 |
Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cell Extracts; Chromatography, Liquid; Cyclopropanes; Darunavir; Humans; Leukocytes, Mononuclear; Lopinavir; Mass Spectrometry; Oligopeptides; Pyridines; Ritonavir; Sulfonamides | 2014 |
FLAMINGO: how much rosier can antiretroviral therapy get?
Topics: Anti-HIV Agents; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Ritonavir; Sulfonamides | 2014 |
Plasma exchange significantly affects darunavir exposure.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Plasma Exchange; Ritonavir; Sulfonamides; Viral Load | 2014 |
Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens.
Topics: Adult; Algorithms; Antiviral Agents; Cells; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Monocytes; Peptide Hydrolases; Ritonavir | 2014 |
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Topics: Adult; Aged; Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Plasma; Ritonavir; Sulfonamides; Young Adult | 2014 |
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Spain; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.
Topics: Adult; Antiretroviral Therapy, Highly Active; Canada; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Darunavir; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Ritonavir | 2014 |
Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Resistance, Viral; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV-1; Humans; Male; Mutation, Missense; Prospective Studies; Ritonavir; Sulfonamides | 2015 |
Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques.
Topics: Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Darunavir; DNA, Viral; Drug Therapy, Combination; Female; Histone Deacetylase Inhibitors; Hydroxamic Acids; Macaca mulatta; Naphthyridines; Ritonavir; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Sulfonamides; Viremia; Virus Replication; Vorinostat | 2014 |
Use of micellar liquid chromatography to analyze darunavir, ritonavir, emtricitabine, and tenofovir in plasma.
Topics: Adenine; Anti-HIV Agents; Calibration; Chromatography, Liquid; Darunavir; Deoxycytidine; Emtricitabine; Humans; Micelles; Organophosphonates; Ritonavir; Sodium Dodecyl Sulfate; Sulfonamides; Tenofovir | 2014 |
Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Child; Darunavir; Female; HIV Infections; Humans; Male; Ritonavir; Sulfonamides | 2014 |
Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; Aspergillus; Darunavir; Drug Interactions; Emtricitabine; HIV Infections; HIV Protease Inhibitors; Humans; Lung Abscess; Male; Ritonavir; Tenofovir; Treatment Outcome; Voriconazole | 2015 |
The fate of ritonavir in the presence of darunavir.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; beta-Cyclodextrins; Chemistry, Pharmaceutical; Darunavir; Excipients; Hypromellose Derivatives; Methylcellulose; Povidone; Powders; Ritonavir; Solubility; Sulfonamides | 2014 |
Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemokine CCL5; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Envelope Protein gp120; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Oxazines; Peptide Fragments; Phylogeny; Piperazines; Pyridones; Receptors, CCR5; Receptors, CXCR4; Ritonavir; Sulfonamides; Triazoles; Viral Load; Viral Tropism | 2014 |
[HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART].
Topics: AIDS Dementia Complex; Anti-Retroviral Agents; Central Nervous System; Cognition Disorders; Darunavir; Disease Progression; Drug Resistance, Viral; Drug Substitution; HIV; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viremia; Zidovudine | 2014 |
Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity.
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Administration Schedule; Drug Synergism; HIV Infections; Humans; Lamivudine; Ritonavir; Sulfonamides; Treatment Outcome | 2015 |
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir; Sulfonamides; Survival Analysis; Treatment Outcome; Viral Load | 2015 |
Estimation of the Binding Free Energy of AC1NX476 to HIV-1 Protease Wild Type and Mutations Using Free Energy Perturbation Method.
Topics: Darunavir; HIV Protease; HIV-1; Models, Molecular; Mutation; Ritonavir | 2015 |
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Female; Hepatitis C; HIV Infections; Humans; Liver Function Tests; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2015 |
Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.
Topics: Adult; Bacterial Translocation; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Ritonavir; Sulfonamides; Viral Load; Viremia | 2015 |
Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.
Topics: Adolescent; Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Cohort Studies; Darunavir; Female; HIV Infections; Humans; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Ritonavir; Sulfonamides; Young Adult | 2015 |
Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Nervous System; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2016 |
Development and validation of a rapid ultra high performance liquid chromatography with tandem mass spectrometry method for the simultaneous determination of darunavir, ritonavir, and tenofovir in human plasma: Application to human pharmacokinetics.
Topics: Chromatography, High Pressure Liquid; Darunavir; HIV Protease Inhibitors; Humans; Ritonavir; Tandem Mass Spectrometry; Tenofovir | 2015 |
Outcomes in treatment with darunavir/ritonavir in ART-experienced paediatric patients.
Topics: Child; Child, Preschool; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Sulfonamides | 2015 |
Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
Topics: Adult; Case-Control Studies; Coinfection; Darunavir; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Ritonavir | 2015 |
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.
Topics: Adult; Anti-HIV Agents; Ascorbic Acid; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunophenotyping; Male; Middle Aged; Niacin; Pyridoxine; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; T-Lymphocytes; Zinc Compounds | 2016 |
Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
Topics: Adult; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Models, Biological; Pregnancy; Ritonavir; Young Adult | 2016 |
Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
Topics: ADP-ribosyl Cyclase 1; Adult; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coinfection; Darunavir; Female; Gene Expression; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; HLA-DR Antigens; Humans; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Ritonavir; Viral Load | 2016 |
[Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting].
Topics: Adult; Aged; Darunavir; Drug Combinations; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Retrospective Studies; Ritonavir | 2015 |
Extremely high HIV-1 viral load in a patient with undiagnosed clinical indicator disease for HIV infection.
Topics: AIDS Dementia Complex; Anti-HIV Agents; Black People; CD4 Lymphocyte Count; Darunavir; Delayed Diagnosis; Dermatitis, Atopic; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV-1; Humans; Immunosuppressive Agents; Middle Aged; Predictive Value of Tests; Prednisolone; Raltegravir Potassium; Ritonavir; Treatment Outcome; Viral Load | 2015 |
The use of unboosted darunavir in the setting of ritonavir intolerance: three case reports.
Topics: Darunavir; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir | 2016 |
Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; Health Expenditures; Health Services; HIV Infections; Humans; Male; Medicaid; Medication Adherence; Middle Aged; Models, Econometric; Propensity Score; Retrospective Studies; Ritonavir; Socioeconomic Factors; United States | 2016 |
Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Hemodynamics; HIV Infections; HIV-1; Humans; Lipid Metabolism; Lipids; Raltegravir Potassium; Ritonavir; Treatment Outcome | 2016 |
Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.
Topics: Adult; Area Under Curve; Computer Simulation; Darunavir; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Middle Aged; Models, Theoretical; Rifampin; Ritonavir; Young Adult | 2016 |
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Topics: Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotyping Techniques; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Point-of-Care Systems; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2015 |
Chronic Effects of Ethanol and/or Darunavir/Ritonavir on U937 Monocytic Cells: Regulation of Cytochrome P450 and Antioxidant Enzymes, Oxidative Stress, and Cytotoxicity.
Topics: Antioxidants; Blotting, Western; Catalase; Cell Line; Cell Survival; Central Nervous System Depressants; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Darunavir; Ethanol; HIV Protease Inhibitors; Humans; Monocytes; Oxidative Stress; Peroxiredoxin VI; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Messenger; Superoxide Dismutase; Superoxide Dismutase-1 | 2016 |
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load | 2016 |
Cerebrospinal fluid viral escape and acute encephalitis in a patient on boosted protease inhibitor monotherapy.
Topics: Adult; Brain; Darunavir; Encephalitis, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Magnetic Resonance Imaging; Male; Ritonavir; Treatment Failure; Viral Load | 2016 |
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir | 2016 |
Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.
Topics: Adolescent; Anti-Retroviral Agents; CD4 Lymphocyte Count; Child; Darunavir; Drug Resistance, Multiple, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nitriles; Poverty; Pyridazines; Pyrimidines; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2016 |
FDA notifications. Once daily dosing of darunavir approved.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2011 |
Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients.
Topics: 2-Naphthylamine; Anilides; Carbamates; Coinfection; Cyclopropanes; Darunavir; Hepatitis C; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.
Topics: Anti-HIV Agents; Antiviral Agents; Area Under Curve; Carbamates; Coinfection; Darunavir; Diuretics; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidines; Renal Insufficiency; Ritonavir; Treatment Outcome; Valine | 2016 |
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Rilpivirine; Ritonavir; Young Adult | 2016 |
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Female; HIV Infections; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Young Adult | 2016 |
Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Long Term Adverse Effects; Lopinavir; Male; Retrospective Studies; Ritonavir; RNA, Viral; Spain; Sulfonamides; Viral Load; Young Adult | 2016 |
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
Topics: Anti-Retroviral Agents; Darunavir; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Observational Studies as Topic; Ritonavir; RNA, Viral | 2016 |
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.
Topics: Adolescent; Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; Treatment Failure; Viral Load; Young Adult | 2017 |
Life-threatening digoxin toxicity due to drug-drug interactions in an HIV-positive man.
Topics: Darunavir; Digoxin; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Renal Insufficiency; Ritonavir | 2017 |
Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; Drug Therapy, Combination; HIV Infections; Humans; Male; Ritonavir; Semen; Viral Load | 2016 |
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Topics: Acute Kidney Injury; Adult; Albuminuria; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Cross-Sectional Studies; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Proteinuria; Ritonavir | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Viral Load | 2017 |
Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly Active; Cohort Studies; Darunavir; Drug Resistance, Viral; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retreatment; Ritonavir; RNA, Viral; Salvage Therapy; Viral Load; Virus Replication; Young Adult | 2017 |
HIV positive patient with HSV-2 encephalitis: case report.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Substitution; Encephalitis, Herpes Simplex; Herpesvirus 2, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Rilpivirine; Ritonavir; Virus Replication | 2016 |
[Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
Topics: Adult; Cobicistat; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Prospective Studies; Ritonavir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2016 |
Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal.
Topics: Aged; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Blood Chemical Analysis; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; International Normalized Ratio; Male; Ritonavir; Warfarin | 2017 |
[Darunavir in special situations].
Topics: Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Male; Pregnancy; Pregnancy Complications, Infectious; Ritonavir | 2016 |
[Present and future of darunavir for the treatment of human immunodeficiency virus infection].
Topics: Clinical Trials as Topic; Darunavir; Drug Combinations; Forecasting; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2016 |
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; RNA, Viral; Viral Load; Viremia; Young Adult | 2017 |
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
Topics: Antirheumatic Agents; Antitubercular Agents; Cells, Cultured; Cobicistat; Darunavir; Drug Interactions; Drug Therapy, Combination; Hepatocytes; HIV Infections; HIV-1; Humans; Metabolic Clearance Rate; Mycobacterium tuberculosis; Rifampin; Ritonavir; Tuberculosis, Pulmonary | 2017 |
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
Topics: Anti-HIV Agents; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir | 2017 |
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Middle Aged; Registries; Regression Analysis; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2017 |
The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.
Topics: Bayes Theorem; Darunavir; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Ritonavir; Tenofovir | 2017 |
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; British Columbia; Canada; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2017 |
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load | 2017 |
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; Brachial Artery; Cardiovascular Diseases; Carotid Intima-Media Thickness; CD4 Lymphocyte Count; Chi-Square Distribution; Cyclopropanes; Darunavir; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation Mediators; Italy; Lipids; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Risk Factors; Ritonavir; Time Factors; Treatment Outcome; Vasodilation | 2017 |
A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lymph Nodes; Medication Adherence; Models, Biological; Mutation; Ritonavir; Tenofovir; Viral Load | 2017 |
Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.
Topics: Adult; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Darunavir; Drug Interactions; Female; Healthy Volunteers; HIV Protease Inhibitors; Humans; Liver Diseases; Lopinavir; Male; Middle Aged; Models, Biological; Ritonavir; Young Adult | 2017 |
Conference on Retroviruses and Opportunistic Infections 2017 highlights.
Topics: AIDS-Related Opportunistic Infections; Amides; Anti-HIV Agents; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Darunavir; Disease Management; Disease Susceptibility; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Penis; Piperazines; Pyridones; Ritonavir; Treatment Outcome; Washington | 2017 |
Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
Topics: Cell Line; Cytochrome P-450 CYP3A; Darunavir; Ethanol; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Microsomes, Liver; Molecular Docking Simulation; Monocytes; Ritonavir; Virus Replication | 2017 |
Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.
Topics: Adult; Aged; Cross-Sectional Studies; Darunavir; Diet Surveys; Drug Therapy, Combination; Feeding Behavior; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Outpatients; Patient Education as Topic; Ritonavir; Young Adult | 2017 |
Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.
Topics: Darunavir; Drug Therapy, Combination; Female; Fetus; HIV Protease Inhibitors; Humans; Maternal-Fetal Exchange; Models, Biological; Placenta; Pregnancy; Ritonavir | 2018 |
Sinus bradycardia induced by darunavir-ritonavir in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Bradycardia; Darunavir; Female; HIV Protease Inhibitors; Humans; Ritonavir | 2017 |
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome; Viral Load | 2017 |
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; pol Gene Products, Human Immunodeficiency Virus; Ritonavir; Viral Load | 2018 |
Nivolumab in HIV-related non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD4 Lymphocyte Count; Cisplatin; Darunavir; Deoxycytidine; Docetaxel; Gemcitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Oxazines; Piperazines; Pyridones; Ritonavir; Vinorelbine | 2017 |
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
Topics: Aged; Anti-HIV Agents; Cobicistat; Dabigatran; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Ritonavir | 2018 |
Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Darunavir; Eswatini; Female; HIV Infections; HIV-1; Humans; Kenya; Lesotho; Lopinavir; Male; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zambia | 2018 |
Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Topics: Adolescent; Atazanavir Sulfate; Child; Cohort Studies; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Longitudinal Studies; Male; Ritonavir; Viral Load; Young Adult | 2018 |
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Rilpivirine; Ritonavir; Viral Load; Young Adult | 2018 |
Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2018 |
Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.
Topics: Anti-HIV Agents; Antifungal Agents; Darunavir; Drug Interactions; Histoplasmosis; HIV Infections; Humans; Itraconazole; Male; Mental Disorders; Middle Aged; Plasma; Ritonavir | 2018 |
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2018 |
Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.
Topics: Child; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Ritonavir | 2018 |
Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Darunavir; Drug Dosage Calculations; Equivalence Trials as Topic; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir | 2018 |
Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Belgium; Darunavir; Female; HIV Infections; Humans; Male; Retrospective Studies; Ritonavir | 2018 |
Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
Topics: Administration, Oral; Animals; Darunavir; Drug Delivery Systems; HIV Infections; HIV Protease Inhibitors; HIV-1; Male; Nanoparticles; Rats; Rats, Sprague-Dawley; Ritonavir | 2018 |
Investigating the Physicochemical Stability of Highly Purified Darunavir Ethanolate Extracted from PREZISTA® Tablets.
Topics: Chemical Phenomena; Chromatography, High Pressure Liquid; Darunavir; Drug Stability; Excipients; HIV Protease Inhibitors; Ritonavir; Tablets; X-Ray Diffraction | 2018 |
Association of antiretroviral therapy with brain aging changes among HIV-infected adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Brain; Darunavir; HIV Infections; Humans; Middle Aged; Neurodegenerative Diseases; Ritonavir; Young Adult | 2018 |
Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Randomized Controlled Trials as Topic; Ritonavir; Telomere; Tenofovir | 2018 |
Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.
Topics: Adult; Aged; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Retrospective Studies; Ritonavir; Treatment Outcome; Young Adult | 2019 |
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Inflammation; Male; Middle Aged; Prospective Studies; Ritonavir | 2018 |
Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
Topics: Adult; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; Viral Load | 2018 |
Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Viral Load | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; HIV; HIV Infections; Humans; Lamivudine; Ritonavir | 2019 |
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.
Topics: Anti-HIV Agents; Computer Simulation; Darunavir; Dose-Response Relationship, Drug; Female; Gestational Age; HIV Seropositivity; Humans; Models, Theoretical; Population; Pregnancy; Pregnancy Complications, Infectious; Ritonavir | 2019 |
Therapeutic drug monitoring of darunavir/ritonavir in pregnancy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Long-term improvement in renal, bone, lipid parameters, and CD4/CD8 ratio in HIV-infected patients switching to a dual therapy with lamivudine plus boosted darunavir.
Topics: Adult; Aged; Anti-HIV Agents; Bone Density; CD4-CD8 Ratio; Darunavir; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Function Tests; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2019 |
Treatment of prolonged tacrolimus toxicity using phenytoin in a haemodialysis patient.
Topics: Darunavir; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Male; Middle Aged; Phenytoin; Renal Dialysis; Ritonavir; Tacrolimus | 2019 |
Does less equal more yet?
Topics: Darunavir; HIV Infections; Humans; Lopinavir; Ritonavir; RNA | 2019 |
Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy.
Topics: Adult; Anti-HIV Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2019 |
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
Topics: Adult; Africa, Western; Algorithms; Clinical Decision-Making; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Raltegravir Potassium; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load | 2019 |
Are 96-week data enough for doravirine to DRIVE FORWARD?
Topics: Adult; Darunavir; Double-Blind Method; HIV Infections; HIV-1; Humans; Ritonavir | 2020 |
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Directly Observed Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Ritonavir; Tenofovir; Treatment Outcome | 2020 |
Darunavir Pharmacokinetics With an Increased Dose During Pregnancy.
Topics: Adult; Darunavir; Dose-Response Relationship, Drug; Drug Combinations; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Statistics as Topic; Young Adult | 2020 |
Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Viral Load | 2020 |
Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Retrospective Studies; Rilpivirine; Ritonavir; Spain; Viral Load | 2020 |
COVID-19 in kidney transplant recipients.
Topics: Aged; Betacoronavirus; Cobicistat; Colchicine; Coronavirus Infections; COVID-19; Cytokines; Darunavir; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lopinavir; Male; Middle Aged; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tacrolimus; Transplant Recipients; Treatment Outcome | 2020 |
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Topics: Adult; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Ciliopathies; Cobicistat; Common Cold; Coronavirus Infections; Cough; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deprescriptions; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Fatigue; Female; Glucocorticoids; Graft Rejection; Humans; Hydroxychloroquine; Immunocompromised Host; Immunosuppressive Agents; Interleukin-10; Interleukin-1beta; Interleukin-6; Interleukin-8; Kidney Diseases, Cystic; Kidney Failure, Chronic; Kidney Transplantation; Leber Congenital Amaurosis; Lopinavir; Methylprednisolone; Optic Atrophies, Hereditary; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tacrolimus | 2020 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Darunavir does not prevent SARS-CoV-2 infection in HIV patients.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Darunavir; HIV Infections; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Republic of Korea; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2 | 2020 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Ceftriaxone; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Methylprednisolone; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Convalescence; Coronavirus Infections; COVID-19; Critical Illness; Darunavir; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Humans; Hydroxychloroquine; Lopinavir; Multiple Organ Failure; Pandemics; Pneumonia, Viral; Ritonavir; RNA, Viral; SARS-CoV-2; Torsades de Pointes | 2020 |
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Topics: Darunavir; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Retrospective Studies; Ritonavir | 2020 |
Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study.
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Ritonavir | 2020 |
Covid-19: A systemic disease treated with a wide-ranging approach: A case report.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Azithromycin; China; Coronavirus Infections; COVID-19; Darunavir; Disease Progression; Enoxaparin; Humans; Hydroxychloroquine; Male; Middle Aged; Noninvasive Ventilation; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; Ritonavir | 2020 |
Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Darunavir; Electrocardiography; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Male; Middle Aged; Ritonavir; SARS-CoV-2 | 2021 |
Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations.
Topics: Cobicistat; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir | 2021 |
Long-term virological effectiveness with darunavir/ritonavir-based salvage therapy in people living with HIV/AIDS from São Paulo, Brazil.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Long-Term Survivors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Treatment Outcome; Viral Load | 2020 |
Morning vs. evening administration of antiviral therapy in COVID-19 patients. A preliminary retrospective study in Ferrara, Italy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Blood Gas Analysis; C-Reactive Protein; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Chronotherapy; Drug Therapy, Combination; Hospital Mortality; Humans; Italy; Length of Stay; Leukocyte Count; Middle Aged; Oxygen; Pandemics; Partial Pressure; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Ritonavir; Treatment Outcome; Viral Load | 2020 |
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Female; Follow-Up Studies; HIV Protease Inhibitors; Humans; Hydroxychloroquine; Male; Methylprednisolone; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV.
Topics: Darunavir; HIV Infections; Humans; Lipids; Nanoparticles; Polymers; Ritonavir | 2020 |
COVID-19 in a young liver transplant recipient: caution for drug-drug interactions.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Darunavir; Drug Interactions; Drug Monitoring; Humans; Hydroxychloroquine; Immunosuppressive Agents; Liver Transplantation; Male; Pandemics; Pneumonia, Viral; Prednisone; Risk Adjustment; Ritonavir; SARS-CoV-2; Tacrolimus; Transplant Recipients; Treatment Outcome | 2020 |
An infection-oriented approach for thoracic endovascular aortic repair in a SARS-CoV-2 positive patient. A case report.
Topics: Anesthesia, Local; Antibiotic Prophylaxis; Anticoagulants; Antiviral Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Betacoronavirus; Blood Vessel Prosthesis Implantation; Contraindications, Procedure; Coronavirus Infections; COVID-19; Darunavir; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endovascular Procedures; Enoxaparin; Female; Humans; Hydroxychloroquine; Infection Control; Infectious Disease Transmission, Patient-to-Professional; Intraoperative Complications; Intubation, Intratracheal; Middle Aged; Nasopharynx; Operating Rooms; Pandemics; Patient Isolation; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Spinal Cord Ischemia; Vertebral Artery | 2020 |
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.
Topics: Betacoronavirus; Binding Sites; Biophysical Phenomena; Catalytic Domain; Computational Biology; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Darunavir; Drug Repositioning; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Pandemics; Pneumonia, Viral; Ritonavir; Saquinavir; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |
Changes in weight and BMI with first-line doravirine-based therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Mass Index; CD4 Lymphocyte Count; Darunavir; HIV Infections; Humans; Pyridones; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2021 |
Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina.
Topics: Anti-HIV Agents; Argentina; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Raltegravir Potassium; Retrospective Studies; Ritonavir; Viral Load | 2021 |
The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years.
Topics: Adolescent; Child; Child, Preschool; Darunavir; Follow-Up Studies; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir | 2021 |
Iatrogenic Cushing syndrome following lumbar medial branch block in a patient with HIV on ritonavir and darunavir.
Topics: Cushing Syndrome; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Iatrogenic Disease; Ritonavir | 2021 |
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Atazanavir Sulfate; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Drug Therapy, Combination; Early Medical Intervention; Emtricitabine; Humans; Lamivudine; Lopinavir; Molecular Docking Simulation; Nucleosides; Protease Inhibitors; Ritonavir; SARS-CoV-2 | 2021 |
Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6".
Topics: COVID-19; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-6; Ritonavir; SARS-CoV-2 | 2021 |
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Darunavir; Disease Progression; Drug Combinations; Female; Hospitals; Hospitals, University; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pyrazines; Referral and Consultation; Retrospective Studies; Ritonavir; Thailand; Treatment Outcome; Young Adult | 2021 |
Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients.
Topics: Action Potentials; Acute Disease; Aged; Anti-Bacterial Agents; Biomarkers; Convalescence; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Guillain-Barre Syndrome; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Interleukin-6; Interleukin-8; Lopinavir; Male; Neural Conduction; Peripheral Nervous System; Prognosis; Respiratory Insufficiency; Ritonavir; SARS-CoV-2 | 2021 |
Implications of phase solubility/miscibility and drug-rich phase formation on the performance of co-amorphous materials: The case of Darunavir co-amorphous materials with Ritonavir and Indomethacin as co-formers.
Topics: Darunavir; Indomethacin; Pharmaceutical Preparations; Ritonavir; Solubility | 2021 |
Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
Topics: Adult; Cobicistat; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir; Treatment Outcome | 2022 |
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Lopinavir; Quality of Life; Ritonavir; South Africa | 2022 |
Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA; Romania; Viral Load | 2022 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.
Topics: Contraceptive Agents; Darunavir; Female; HIV Infections; Humans; Levonorgestrel; Progestins; Rilpivirine; Ritonavir | 2022 |
Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cohort Studies; Darunavir; Female; HIV Infections; Humans; Infant; Milk, Human; Mothers; Prospective Studies; Raltegravir Potassium; Rilpivirine; Ritonavir; Switzerland | 2022 |
Epidemiology, diagnosis and treatment of early COVID-19 patients in Jiaxing City, Zhejiang Province, China, January to March 2020.
Topics: China; Cities; Cobicistat; COVID-19; Darunavir; Female; Humans; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir | 2022 |
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Follow-Up Studies; HIV Infections; HIV-1; Humans; Raltegravir Potassium; Ritonavir; Treatment Outcome; Viral Load | 2023 |
Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal.
Topics: Aging, Premature; Animals; Anti-HIV Agents; Atazanavir Sulfate; Cellular Senescence; Darunavir; HIV Infections; HIV Protease Inhibitors; Mice; Ritonavir | 2023 |
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Retrospective Studies; Ritonavir; Viral Load | 2022 |
Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Topics: Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily G, Member 2; Darunavir; Drug Interactions; Lopinavir; Neoplasm Proteins; Protease Inhibitors; Ritonavir; Rosuvastatin Calcium | 2023 |
Immune recovery among Romanian HIV/AIDS patients receiving darunavir/ritonavir or darunavir/cobicistat regimens in cART management: A three-year study.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Retrospective Studies; Ritonavir; Romania; Viral Load | 2023 |
PRESTIGIO RING: "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir".
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Seropositivity; HIV-1; Humans; Raltegravir Potassium; Ritonavir; RNA; Treatment Outcome; Viral Load | 2023 |
HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2023 |